[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 184
1. Hennessy SA, Dengel LT, Hranjec T, Slingluff CL Jr: A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage. Ann Surg Oncol; 2010 Sep;17(9):2465-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage.
  • BACKGROUND: Large centers have described triangular intermuscular space (TIS) sentinel nodes (SNs) for some melanomas of the back.
  • Among 293 patients with upper back melanoma, data were collected on those with TIS SN.
  • RESULTS: Fourteen patients (5%) with melanoma of the upper back had a TIS SN, 6 of whom (43%) were incorrectly identified at lymphoscintigraphy as axillary, and 11 of whom (79%) had a concurrent axillary SN.
  • We recommend directed evaluation for TIS SN in patients with upper back melanomas and recommend clearing the TIS at the time of TIS SN biopsy.
  • Melanoma can metastasize to TIS SN, and we discuss considerations for management of the axilla in patients with positive TIS nodes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2001 Feb;88(2):305-8 [11167886.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):570-82 [12679402.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):179S-85S [15023748.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):120-30 [8129482.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):964-6 [8683322.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):195-204 [10437842.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):877-85 [16257796.001]
  • [Cites] Ann Plast Surg. 2010 Jan;64(1):52-4 [20023455.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):811 [10622512.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1168-72 [11030873.001]
  • (PMID = 20221903.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI078875-01A1; United States / NIAID NIH HHS / AI / T32 AI078875; United States / NIAID NIH HHS / AI / T32 AI078875-02; United States / NIAID NIH HHS / AI / T32 AI078875-01A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS268192; NLM/ PMC3033783
  •  go-up   go-down


2. Cózar MP, Ferrer-Rebolleda J, Redal MC, Moreno A, Tortajada L, Casáns I, Romero C: [Sentinel lymph node biopsy in cutaneous non-melanoma malignancies]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):10-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sentinel lymph node biopsy in cutaneous non-melanoma malignancies].
  • [Transliterated title] Biopsia selectiva de ganglio centinela en tumores cutáneos no melanoma.
  • PURPOSE: To assess the feasibility of the Sentinel lymph node biopsy (SLNB) technique in cutaneous non-melanoma malignancies.
  • The SLN position was marked on the skin and after a correct localization in the surgical field with a gamma probe the SLN was obtained.
  • RESULTS: Lymphoscintigraphy detected the sentinel node in 88,8 % of our studies (the SLN was not observed in a patient with a Merkel's tumour on the back).
  • CONCLUSIONS: Sentinel node biopsy can be applied to certain cutaneous non-melanoma malignancies.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Child. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / radionuclide imaging. Dermatofibrosarcoma / secondary. False Negative Reactions. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Aggregated Albumin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540005.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


3. Bardarov S, Michael CW, Lucas D, Pang Y, Pu RT: Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor. Diagn Cytopathol; 2008 Oct;36(10):754-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor.
  • We report a case of metastatic malignant melanoma resembling a malignant peripheral sheath tumor, which posed a significant diagnostic challenge.
  • Five years ago the patient was diagnosed with melanoma on the back with Clark level of IV.
  • The melanoma was excised with clear margins and sentinel lymph nodes were negative.
  • Careful examination of patient's previous slides revealed an area of spindle cell melanoma adjacent to a nodular type melanoma.
  • Based on the patient's previous history, current clinico-pathologic presentation and immunohistochemical profile, the diagnosis of metastatic malignant melanoma resembling peripheral nerve sheath tumor was favored over the diagnosis of metastatic malignant spindle cell neoplasm of unknown primary site, which by itself is very rare clinical scenario.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Melanoma / diagnosis. Melanoma / secondary. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Lung / metabolism. Lung / pathology. Male. Prognosis. S100 Proteins / metabolism. Vimentin / metabolism


Advertisement
4. Kim DH, Choi KH, Cho YD: Clear cell sarcoma of the upper thoracic back muscle. J Korean Neurosurg Soc; 2009 Feb;45(2):112-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of the upper thoracic back muscle.
  • Clear cell sarcoma (CCS), also called malignant melanoma of soft parts, is a rare malignant soft tissue tumor and is often associated with tendons or aponeuroses.
  • We report an extremely rare case of CCS originated in the upper thoracic back muscle.
  • To our knowledge, this case is the second report of CCS of the back muscle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg Oncol. 2006;4:48 [16893467.001]
  • [Cites] Skeletal Radiol. 2000 Apr;29(4):187-95 [10855466.001]
  • [Cites] Arch Pathol Lab Med. 2006 Mar;130(3):343-8 [16519562.001]
  • [Cites] Skeletal Radiol. 2005 Sep;34(9):543-6 [16132975.001]
  • [Cites] Skeletal Radiol. 2005 Mar;34(3):167-70 [15592669.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):969-75 [10491522.001]
  • [Cites] Skeletal Radiol. 1999 Apr;28(4):240-3 [10384998.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1197-204 [1463095.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):405-13 [6614306.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):63-7 [15104285.001]
  • [Cites] Cytojournal. 2007;4:15 [17631685.001]
  • [Cites] Singapore Med J. 2007 Jul;48(7):e203-5 [17609816.001]
  • [Cites] J Surg Oncol. 2007 May 1;95(6):519-22 [17192915.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):58-9 [17391618.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):152-6 [17227118.001]
  • [Cites] J Orthop Sci. 2004;9(2):171-4 [15045547.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):121-5 [12935923.001]
  • [Cites] Can Assoc Radiol J. 2002 Oct;53(4):237-40 [12391930.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):659 [16261586.001]
  • (PMID = 19274123.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651559
  • [Keywords] NOTNLM ; Back muscle / Clear cell sarcoma
  •  go-up   go-down


5. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • Collision (contiguous) tumors of the skin can result in misleading clinicopathological presentations, and the choice of appropriate diagnostic techniques may prevent incomplete diagnosis and management.
  • We report 2 cases of collision tumors involving amelanotic malignant melanoma of the back.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • The other patient is a 71-yr-old male with a 1 cm exophytic lesion on the back, which was determined microscopically to be melanoma, and a 0.6 cm papule on the back.
  • This lesion was composed of 2 distinct contiguous neoplastic infiltrates, the predominant component being an atypical fibroxanthoma and the smaller component an amelanotic melanoma (primary vs metastatic), with diagnostic confirmation requiring multiple immunohistochemical stains.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Nguyen BD: Scintigraphic imaging of a nuchal sentinel node. Clin Nucl Med; 2005 May;30(5):347-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The author presents a case of upper back melanoma with unusual nuchal sentinel node demonstrated by technetium-99m filtered sulfur colloid scintigraphy.
  • [MeSH-major] Lymph Nodes / radionuclide imaging. Melanoma / radionuclide imaging. Melanoma / secondary. Neck / radionuclide imaging. Skin Neoplasms / radionuclide imaging. Technetium Tc 99m Sulfur Colloid

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827411.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


7. Herbert GS, Beshlian KM: The triangular intermuscular space as a site of lymph node metastasis in melanoma of the back. Ann Plast Surg; 2010 Jan;64(1):52-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The triangular intermuscular space as a site of lymph node metastasis in melanoma of the back.
  • We report 3 patients with truncal melanoma, presenting with recurrent disease in the TIS.
  • These cases suggest that in patients with melanoma of the back, the Triangular Intermuscular Space, as the gateway to the axilla, may be an important site of metastatic disease.
  • [MeSH-major] Lymphatic Metastasis / radiography. Melanoma / secondary. Muscle Neoplasms / secondary. Muscle, Skeletal / surgery
  • [MeSH-minor] Back. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023455.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Acar O, Akinci M, Uluocak N, Akbulut F, Kilicaslan I, Gokce O: Paratesticular metastasis of malignant melanoma: a case report. Kaohsiung J Med Sci; 2008 Jun;24(6):315-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular metastasis of malignant melanoma: a case report.
  • We report a case of multimetastatic malignant melanoma that was diagnosed after histopathologic examination of the excised paratesticular mass.
  • Our patient initially visited the neurosurgery clinic due to low back pain.
  • The histopathologic findings were consistent with malignant melanoma.
  • Our case was unique because the malignant melanoma was widely metastatic and involved primarily paratesticular tissues without any invasion of the testis and epididymis.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Genital Neoplasms, Male / secondary. Melanoma / diagnosis. Melanoma / pathology. Scrotum / pathology
  • [MeSH-minor] Back Pain. Biopsy. Epididymis / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Testis / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635417.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


9. Reguiaï Z, Jovenin N, Bernard P, Derancourt C: Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders. Dermatology; 2008;216(4):330-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders.
  • BACKGROUND: Multiple solar lentigines of the upper back and shoulders (MSLBS) have recently been demonstrated as being associated with intense sunburns in the past.
  • OBJECTIVE: To determine the prevalence of MSLBS among patients with cutaneous melanoma.
  • One hundred and twenty-five adult patients, followed up for a cutaneous melanoma, were included, and the prevalence of MSLBS was determined, with comparison of clinical characteristics of patients with and without these lesions.
  • RESULTS: The prevalence of MSLBS among patients with cutaneous melanoma was 37.6%.
  • MSLBS were significantly and independently associated with cutaneous melanoma of the back in multivariate analysis (adjusted odds ratio, OR = 4.3, 95% confidence interval, CI = 1.5-12.3) and with recalled episodes of severe sunburn before the age of 28 (OR = 3.4, 95% CI = 1.3-9.4).
  • CONCLUSION: Large irregularly shaped brown macules of the upper back and shoulders or MSLBS are frequent among adult patients with cutaneous melanoma.
  • They are associated with melanoma located on the upper back.
  • This topographical association further illustrates the relation between past intense sunburns and cutaneous melanoma.
  • MSLBS should be evaluated as an easily recognizable clinical marker of the risk of cutaneous melanoma.
  • [MeSH-major] Lentigo / epidemiology. Skin Neoplasms / epidemiology. Sunburn / complications. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Aged. Back. Female. Humans. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. Odds Ratio. Prevalence. Prospective Studies. Risk Factors. Skin Pigmentation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18230982.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J: Seborrheic keratosislike melanoma with folliculotropism. Arch Dermatol; 2007 Mar;143(3):373-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosislike melanoma with folliculotropism.
  • BACKGROUND: Seborrheic keratosislike melanoma could be one of the most problematic melanoma simulators, and it may be incorrectly treated by electrocautery or cryotherapy.
  • OBSERVATIONS: A 34-year-old man was seen for a conspicuous pigmented lesion on his back that clinically resembled a seborrheic keratosis because of the presence of multiple comedolike openings.
  • Findings from dermoscopic examination showed distinct melanoma criteria (atypical pigmented network, asymmetric globules and dots, and a blue-whitish veil), in addition to multiple comedolike openings.
  • Histopathological examination confirmed a peculiar melanoma variant characterized by prominent folliculotropism and minimal radial spreading.
  • This tumor was not associated with chronic sun-damaged skin.
  • CONCLUSION: Dermoscopy was useful in identifying a particular case of seborrheic keratosislike melanoma with folliculotropism, thus avoiding incorrect treatment.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372102.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ambros-Rudolph CM, Hofmann-Wellenhof R, Richtig E, Müller-Fürstner M, Soyer HP, Kerl H: Malignant melanoma in marathon runners. Arch Dermatol; 2006 Nov;142(11):1471-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in marathon runners.
  • Over the past decade, we observed 8 ultramarathon runners with malignant melanoma.
  • To further evaluate risk factors for malignant melanoma in marathon runners, we examined anamnestic, phenotypic, sun-related, and clinical variables in 210 athletes and compared them with those of an age- and sex-matched control group.
  • OBSERVATIONS: Although control subjects exhibited higher sun sensitivity and more common melanocytic nevi, marathon runners presented with more atypical melanocytic nevi, solar lentigines, and lesions suggestive of nonmelanoma skin cancer.
  • During exercising, most runners wore shorts (96.7%) and shirts (98.6%) that would not or would only partially cover their back and extremities.
  • CONCLUSIONS: Compared with a representative control group, marathon runners presented with an increased risk for malignant melanoma and nonmelanoma skin cancer.
  • [MeSH-major] Melanoma / epidemiology. Running. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116838.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


12. Connolly G, Wladis E, Masselam K, Weinberg DA: Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma. Orbit; 2007 Dec;26(4):291-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contralateral orbital melanoma 28 years following enucleation for choroidal melanoma.
  • A 79-year-old man underwent right enucleation for a choroidal melanoma.
  • Orbital imaging revealed a large left lateral orbital mass, extending back to the orbital apex, which was found on subtotal resection to represent an orbital melanoma.
  • Skin survey was negative, and the prior right choroidal melanoma was the most likely metastatic source.
  • He underwent radiotherapy of the residual tumor at the left orbital apex, as well as radiotherapy of small liver and lung nodules felt to likely represent metastatic melanoma.
  • While melanoma is often considered a highly malignant and lethal tumor, some melanomas are characterized by a more benign course.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097971.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Tarhini AA, Christensen S, Frankel P, Margolin K, Ruel C, Shipe-Spotloe J, DeMark M, Kirkwood JM: Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol; 2009 May 20;27(15_suppl):9028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.
  • METHODS: Phase II study of aflibercept in patients with inoperable stage III or IV melanoma who had received no prior chemotherapy or hormonal therapy.
  • All had AJCC stage IV melanoma (3M1a, 3M1b, 21M1c).
  • Nine patients had primary ocular melanoma, 16 cutaneous and 2 unknown primary site.
  • Grade 3/4 toxicities included cerebral ischemia (1 patient; 4%), confusion (1; 4%), thrombocytopenia (1; 4%), hypertension (7; 26%), hypotension (1; 4%), left ventricular diastolic dysfunction (1; 4%), fatigue (1; 4%), proteinuria (4; 15%), extraocular muscle paresis (1; 4%), renal failure (1; 4%), back pain (1; 4%), headache (1; 4%).
  • Eight (1 M1a, 1M1b, 6M1c; 4 ocular, 3 cutaneous, 1 unknown primary) of the first 21 patients had at least 4 months of PFS (10 out of 27; 2 additional patients with cutaneous melanoma had SD: 1M1a and 1M1c).
  • CONCLUSIONS: Aflibercept can be administered with acceptable toxicity, and exhibits promising antitumor efficacy against advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ben Hadj Hamida F, Fezani M, Ben Amor H, Krifa F, Chaabani L, Khalfallah W, Yacoubi S, Ben Rayana N: [Orbital metastasis from cutaneous melanoma]. J Fr Ophtalmol; 2009 Jun;32(6):425-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital metastasis from cutaneous melanoma].
  • PURPOSE: We report the case of a patient presenting with a one-sided orbital metastasis from a cutaneous melanoma, and analyze clinical features, diagnostic difficulties and prognosis of such metastasis.
  • The computed tomography (CT) disclosed an intraorbital mass with double tonality, rounded and well limited driving back the optic nerve and erasing the limits of the lateral rectus muscle.
  • It was then noted that a cutaneous melanoma of the left foot had been operated ten years before.
  • DISCUSSION: The cutaneous melanoma is a rare cause of orbital metastasis.
  • The diagnosis is often easy, when a primitive tumor is known, but it remains uncertain for a long time.
  • CONCLUSION: Orbital metastases from cutaneous melanoma are rare, generally occurring at the late stage of the disease with a life expectancy not passing one year.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19750592.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Lee TK, Atkins MS, King MA, Lau S, McLean DI: Counting moles automatically from back images. IEEE Trans Biomed Eng; 2005 Nov;52(11):1966-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Counting moles automatically from back images.
  • Density of moles is a strong predictor of malignant melanoma, therefore, enumeration of moles is often an integral part of many studies that look at malignant melanoma.
  • We have developed an unsupervised algorithm for segmenting and counting moles from two-dimensional color images of the back torso region, as part of a study to evaluate the effectiveness of sunscreen.
  • [MeSH-major] Algorithms. Artificial Intelligence. Back / pathology. Image Interpretation, Computer-Assisted / methods. Nevus, Pigmented / pathology. Pattern Recognition, Automated / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285401.001).
  • [ISSN] 0018-9294
  • [Journal-full-title] IEEE transactions on bio-medical engineering
  • [ISO-abbreviation] IEEE Trans Biomed Eng
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Campos-do-Carmo G, Ramos-e-Silva M, Rochael MC, Cuzzi T: Spitzoid melanoma: dermoscopic report and diagnostic discussion. Acta Dermatovenerol Croat; 2010;18(4):252-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spitzoid melanoma: dermoscopic report and diagnostic discussion.
  • He presented a pigmented asymptomatic lesion on the back of his right thigh.
  • Dermoscopic examination revealed uncommon aspects, highly suspect of nodular melanoma, in particular a blue-whitish veil, striae and asymmetric globules.
  • Microscopic findings showed an atypical spitzoid tumor, compatible with spitzoid melanoma.
  • In this report, the importance of dermoscopy as an auxiliary method in the early diagnosis of cutaneous melanomas is emphasized.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Humans. Male. Nevus, Epithelioid and Spindle Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21251441.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


17. Macák J, Zavrelová I: [Melanoma simulating malignant soft tissue tumour]. Cesk Patol; 2005 Oct;41(4):146-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanoma simulating malignant soft tissue tumour].
  • The authors presented the case of an 82-year-old man with primary nodular melanoma of the skin on the back (Breslow 3 mm) which repeatedly metastasized five times to the cervical lymph nodes.
  • The histological pattern assembled malignant mesenchymal tumour - type malignant fibrous histiocytoma.
  • The other above-mentioned melanoma markers were negative.
  • Differential diagnosis includes neurotropic-desmoplastic malignant melanoma, Bednár tumour (pigmented dermatofibrosarcoma protuberans; storiform neurofibroma), malignant peripheral nerve sheath tumour (neurogenic sarcoma) and malignant fibrous histiocytoma.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382990.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


18. Xiao JP, Xu GZ, Miao YJ, Wei WB, Hu SM, Tang X, Wang JZ, Wang GL: [Preliminary results of radiosurgery for uveal melanoma]. Zhonghua Zhong Liu Za Zhi; 2005 Apr;27(4):241-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary results of radiosurgery for uveal melanoma].
  • OBJECTIVE: To evaluate the clinical value of stereotactic radiosurgery (SRS) for uveal melanoma.
  • METHODS: From Jan, 1996 to March, 2004, 16 patients with uveal melanoma were treated with SRS, two by one session (35 Gy, 25 Gy) and fourteen by fractionated SRS (30-55 Gy/2-4F/4-16D).
  • CONCLUSION: Fractionated radiosurgery is safe and effective for uveal melanoma.
  • It is indicated for lesions of limited size (longest diameter < 20 mm, depth < 15 mm) located in the posterior pole or behind the equator at the back of the eyeball.
  • [MeSH-major] Melanoma / surgery. Radiosurgery. Uveal Neoplasms / surgery

  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949429.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Liang KV, Sanderson SO, Nowakowski GS, Arora AS: Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc; 2006 Apr;81(4):511-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant melanoma of the gastrointestinal tract.
  • Malignant melanoma is one of the most common malignancies to metastasize to the gastrointestinal (GI) tract.
  • Metastases to the GI tract can present at the time of primary diagnosis or decades later as the first sign of recurrence.
  • We report 2 cases of malignant melanoma metastatic to the GI tract, followed by a review of the literature.
  • The first case is a 72-year-old man who underwent resection of superficial spreading melanoma on his back 13 years previously who presented with dysphagia.
  • A biopsy specimen of a mucosal fold in a gastric fundus noted during endoscopy was taken and revealed metastatic malignant melanoma, which was resected 1 month later.
  • Three weeks later, the patient was found to have an ulcerated jejunal metastatic melanoma mass, which was also resected.
  • The second case is a 63-year-old man with an ocular melanoma involving the chorold of the left eye that had been diagnosed 4 years previously, which had been excised several times, who presented with anorexia, dizziness, and fatigue.
  • He underwent adjuvant radiation therapy, chemotherapy, and surgical resection of the gastric melanoma metastasis.
  • In patients with a history of melanoma, a high index of suspicion for metastasis must be maintained if they present with seemingly unrelated symptoms.
  • Diagnosis requires careful inspection of the mucosa for metastatic lesions and biopsy with special immunohistochemical stains.
  • [MeSH-major] Choroid Neoplasms / pathology. Jejunal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Fatal Outcome. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610571.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Breza TS, Magro CM: CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol; 2005 Nov;32(10):685-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype.
  • BACKGROUND: The histological diagnosis of malignant melanoma can be challenging.
  • Immunohistochemical techniques may define a critical role in certain cases, specifically in establishing a primary diagnosis of melanoma.
  • CD34 is a hemopoietic stem cell antigen expressed in bone marrow and endothelial cells, and may also be expressed in vascular and spindle cell tumors; it is generally negative in malignant melanoma.
  • CASE REPORT: An 83-year-old white female presented with a 3-4 mm area on her right upper back, which had been present for several years.
  • DISCUSSIONS: We present a case of malignant melanoma of nodular subtype, which strongly expressed CD34.
  • The spectrum of abnormal phenotypes in malignant melanoma is reviewed, and a possible explanation for the presence of CD34 is discussed.
  • This case demonstrates the potential of malignant melanoma to express CD34, defining an infrequently recognized aberrant phenotype.
  • [MeSH-major] Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Melanoma / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Aged, 80 and over. Antigens, Neoplasm. Female. Humans. Immunophenotyping. MART-1 Antigen. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Neoplasm Proteins / immunology. S100 Proteins / analysis. S100 Proteins / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293181.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  • [Number-of-references] 30
  •  go-up   go-down


21. Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME: Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol; 2007 May;56(5):768-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the anatomic distribution of melanoma and sex.
  • BACKGROUND: Anatomic distribution of melanoma, thought to be different between men and women, has not been studied in the United States since the 1970s, although lifestyle and clothing habits have changed since then.
  • OBJECTIVE: To determine whether the anatomic distribution of melanoma varied between men and women at our institution in 2004 and in the 1970s, and to assess whether the anatomic distribution has changed over time.
  • RESULTS: For the 2004 patients, males had an increased relative risk compared to females of developing a melanoma on their head and neck (relative risk ratio [RRR] = 3.33; P = .01).
  • For the 1970s patients, this difference was not found, but males in the 1970s had higher odds of developing melanoma on their upper back, chest, and abdomen, while females in the 1970s had higher odds of developing melanoma on the upper extremity and lower extremity, particularly the lower legs and feet.
  • Examining differences over time, we found that women in 2004 had a decreased relative risk of developing a melanoma on the lower extremities as opposed to the trunk as compared to the 1970s (RRR = 0.42; P < .01).
  • We also found that women had increased odds of developing a melanoma on the chest in 2004 compared to the 1970s (OR = 2.65; P = .04), while men had increased odds of developing a melanoma on their lower legs in 2004 compared to the 1970s (OR = 3.18; P = .02).
  • LIMITATIONS: The study was performed at a single academic center and the results may not generalize to all melanoma populations.
  • CONCLUSIONS: There were significant differences between men and women in the anatomic distribution of melanoma in 2004 patients and in 1970s patients, but the nature of those differences changed over time.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337091.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Forman SB, Vidmar DA, Ferringer TC: Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma. J Cutan Pathol; 2008 Feb;35(2):203-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma.
  • We report the case of an immunocompetent 79-year-old white man with a history of melanoma in situ on the back with a collision tumor composed of a Merkel cell carcinoma (MCC) and lentigo maligna melanoma on the left cheek.
  • The atypical melanocytes of lentigo maligna melanoma expressed Melan-A and S-100.
  • Prior reports of MCC in collision with non-melanoma skin cancers are reviewed.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190446.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Vernadakis S, Rallis G, Danias N, Serafimidis C, Christodoulou E, Troullinakis M, Legakis N, Peros G: Metastatic melanoma of the gallbladder: an unusual clinical presentation of acute cholecystitis. World J Gastroenterol; 2009 Jul 21;15(27):3434-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma of the gallbladder: an unusual clinical presentation of acute cholecystitis.
  • Metastatic disease from cutaneous melanoma can affect all organs of the body, and varies in its biological behavior and clinical presentation.
  • Two years ago, he underwent surgical removal of a primary cutaneous melanoma on his right upper back.
  • Pathological examination revealed the presence of malignant melanoma with a metastatic lesion of the gallbladder.
  • [MeSH-major] Cholecystitis, Acute / etiology. Gallbladder / pathology. Melanoma / complications. Melanoma / pathology. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Cholecystitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):815-6 [11087651.001]
  • [Cites] Chirurg. 2000 Dec;71(12):1517-20 [11195075.001]
  • [Cites] Surg Today. 2003;33(2):135-7 [12616378.001]
  • [Cites] Pathologe. 2004 Mar;25(2):155-9 [15011002.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Br J Radiol. 1982 Nov;55(659):873-4 [7139246.001]
  • [Cites] J Clin Ultrasound. 1994 Jun;22(5):342-7 [8046045.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):279-82 [9068751.001]
  • [Cites] Hematol Oncol Clin North Am. 1998 Aug;12(4):877-902, viii [9759585.001]
  • [Cites] Am Surg. 1998 Dec;64(12):1174-6 [9843339.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):32-9 [9921971.001]
  • [Cites] Cancer. 1964 Oct;17:1323-39 [14236766.001]
  • [Cites] Am Surg. 1990 Jun;56(6):369-73 [2190512.001]
  • (PMID = 19610148.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2712908
  •  go-up   go-down


24. Mao ZG, Jiang CC, Yang F, Thorne RF, Hersey P, Zhang XD: TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis; 2010 Oct;15(10):1211-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4.
  • We report here that activation of caspase-4 is also involved in induction of apoptosis by TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
  • Notably, TRAIL triggered ER stress in melanoma cells as shown by up-regulation of the GRP78 protein and the spliced form of XBP-1 mRNA.
  • Importantly, inhibition of caspase-4 also partially blocked caspase-3 activation, suggesting that activation of caspase-4 may be positive feed-back mechanism to further enhance caspase-3 activation.
  • Collectively, these results show that activation of caspase-4 contributes to TRAIL-induced apoptosis and is associated with induction of ER stress by TRAIL in melanoma cells, and may have important implications for improving therapeutic efficacies of TRAIL in melanoma.
  • [MeSH-major] Apoptosis. Caspases, Initiator / metabolism. Melanoma / metabolism. Melanoma / pathology. TNF-Related Apoptosis-Inducing Ligand / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514521.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Transcription Factors; 0 / molecular chaperone GRP78; 0 / regulatory factor X transcription factors; EC 3.4.22.- / CASP4 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases, Initiator
  •  go-up   go-down


25. Herlyn M: Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer; 2006 Feb 1;118(3):523-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets in melanoma: strategies and challenges for diagnosis and therapy.
  • In coming years, we expect rapid advances in cutaneous melanoma diagnosis and therapy, because of the incorporation of new technologies into experimental and clinical research.
  • Major discoveries in melanoma are often made by investigators outside the field, and the melanoma research community will need to develop a better means of incorporating these advances into their work, to capitalize on the promise they hold for patients.
  • A far greater level of cooperation between labs and clinics will be to bring new technology-based discoveries from bench-to-bedside and back.
  • Metastatic melanoma should become a treatable disease in the next few years, because specific inhibitors are expected for most major targets.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16258898.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


26. White N, Yap LH, Srivastava S: Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective? J Craniofac Surg; 2009 Mar;20(2):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective?
  • An analysis was made of 37 consecutive patients with melanoma for an 8-year period presenting with a clinically N1 neck (a single involved node based on clinical examination and radiologic investigation).
  • There was a mean follow-up of 3 years 10 months after primary diagnosis.
  • We would recommend a modified radical neck dissection for the N1 neck in melanoma with an intraoperative decision being made on which structures to preserve based on position of involved lymph node and adjacent structures, particularly in younger patients.
  • A selective neck dissection should be considered in those patients with significant comorbidity, distant metastatic disease, or primary sites on the back or posterior scalp.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Lymph Node Excision / methods. Melanoma / surgery. Neck Dissection / classification

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258904.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Trost O, Danino AM, Kadlub N, Dalac S, Hervé C, Malka G: [What about sentinel node practice in early-staged cutaneous melanoma in France in 2003?]. Ann Chir Plast Esthet; 2005 Apr;50(2):99-103
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What about sentinel node practice in early-staged cutaneous melanoma in France in 2003?].
  • [Transliterated title] Ganglion sentinelle dans le mélanome malin de bas stade: état des lieux en France en 2003.
  • AIM: The aim of this study was to establish the status of sentinel lymph node (SLN) biopsy procedure in cutaneous melanoma in France in 2002.
  • MATERIAL AND METHODS: This study was based upon the statistics of the main French melanoma centers.
  • The authors asked for the global attitude as far as SLN was concerned, number of cutaneous melanoma diagnosed during year 2002 and of SLN procedures performed, critters of inclusion and postoperative management in each case.
  • Answers were sent back by email.
  • Staffs performing SLN diagnosed a mean of 101 (8-400) melanoma and biopsied a mean of 21 (0-53) sentinel nodes.
  • The others diagnosed a mean of 151 (15-250) melanoma.
  • If 64% are performing SLN, more than 50% of the new melanoma are not included in the trial.
  • [MeSH-major] Melanoma / pathology. Sentinel Lymph Node Biopsy / statistics & numerical data. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820594.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


28. Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC: Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. Int J Cancer; 2006 Aug 1;119(3):636-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis.
  • Two histological characteristics of melanoma consistent with these divergent origins are dermal elastosis in adjacent skin and neval remnants contiguous with the tumor, respectively.
  • To further explore causal heterogeneity in melanoma, we compared sun exposure histories and phenotypic characteristics among a population-based sample of patients newly diagnosed with cutaneous melanoma with and without contiguous neval remnants or dermal elastosis.
  • Tissue blocks were obtained for 141 patients: 53 with superficial spreading melanoma (SSM) of the back, 42 with SSM of head and neck (H & N), and 39 and 7 with lentigo maligna/lentigo maligna melanoma (LM/LMM) of the H & N and back, respectively.
  • Melanomas of the H & N were less likely than those on back to have neval remnants (adjusted OR 0.6, 95% CI 0.3-1.4), but were significantly more likely to have dermal elastosis (adjusted OR 9.3, 95% CI 3.5-25).
  • Less marked associations were observed for melanomas of the back.
  • High levels of sun exposure strongly predicted dermal elastosis for H & N melanomas (OR 22.5, 95% CI 2.1-245), but not for melanomas of the back (OR 2.1, 95% CI 0.4-11).
  • [MeSH-major] Elastic Tissue / pathology. Melanoma / etiology. Nevus / complications. Skin Diseases / complications. Skin Neoplasms / etiology. Sunlight / adverse effects
  • [MeSH-minor] Age Factors. Back. Female. Head and Neck Neoplasms / etiology. Humans. Hutchinson's Melanotic Freckle / etiology. Male. Middle Aged. Odds Ratio. Skin / pathology. Skin / radiation effects

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16572428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA88363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Kitahara S, Morikawa S, Shimizu K, Abe H, Ezaki T: Alteration of angiogenic patterns on B16BL6 melanoma development promoted in Matrigel. Med Mol Morphol; 2010 Mar;43(1):26-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of angiogenic patterns on B16BL6 melanoma development promoted in Matrigel.
  • Because the progression and metastasis of solid tumors depend on their local microcirculation, we sought to characterize tumor angiogenesis three dimensionally in a highly metastatic mouse melanoma model, B16BL6 (B16), injected with Matrigel into the subcutis in the skin on the back of syngeneic C57BL/6 mice.
  • [MeSH-major] Melanoma, Experimental / blood supply. Melanoma, Experimental / pathology. Neovascularization, Pathologic / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] News Physiol Sci. 2003 Apr;18:65-70 [12644622.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45826-32 [12954626.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15240-8 [11278365.001]
  • [Cites] Science. 2008 Apr 4;320(5872):38-41 [18388269.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2520-6 [10811134.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 2):H2547-62 [8997316.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] J Pathol. 1996 Apr;178(4):363-6 [8691311.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2173-80 [16489018.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Chest. 2005 Dec;128(6 Suppl):602S-608S [16373858.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(2):111-7 [1899955.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2043-55 [11395382.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Microvasc Res. 2006 Mar;71(2):69-75 [16545400.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8249-55 [15548691.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):1-15 [17200177.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):85-9 [17602710.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Apr;54(1):53-61 [15780907.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1801-15 [14578181.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Biochemistry. 1982 Nov 23;21(24):6188-93 [6217835.001]
  • [Cites] J Pathol. 2002 Jul;197(3):355-62 [12115882.001]
  • [Cites] Med Mol Morphol. 2005 Mar;38(1):36-42 [16158178.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9 [15308462.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):115-22 [1695694.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):789-96 [11238026.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):107-11 [3881360.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502 [17717633.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Virchows Arch. 2006 Jun;448(6):768-75 [16612622.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • (PMID = 20340003.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


30. Schallreuter KU, Rokos H, Chavan B, Gillbro JM, Cemeli E, Zothner C, Anderson D, Wood JM: Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells. Free Radic Biol Med; 2008 Feb 15;44(4):538-46
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells.
  • Our results confirmed that TR reduces the p-quinone 1,4 benzoquinone and coenzyme Q10-quinone back to HQ and coenzyme Q10-quinol, respectively, while 6BH(4) has the capacity to reduce coenzyme Q10-quinone and the o-quinone produced from 17beta-estradiol.
  • 6BH(4) is present in the cytosol and in the nucleus of epidermal melanocytes and keratinocytes as well as melanoma cells and colocalises with TR/T.
  • [MeSH-major] Biopterin / analogs & derivatives. Keratinocytes / metabolism. Melanocytes / metabolism. Melanoma / metabolism. Quinones / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997383.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinones; 22150-76-1 / Biopterin; BBX060AN9V / Hydrogen Peroxide; EC 1.8.1.9 / Thioredoxin-Disulfide Reductase; EGX657432I / sapropterin
  •  go-up   go-down


31. Geller AC, Johnson TM, Miller DR, Brooks KR, Layton CJ, Swetter SM: Factors associated with physician discovery of early melanoma in middle-aged and older men. Arch Dermatol; 2009 Apr;145(4):409-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with physician discovery of early melanoma in middle-aged and older men.
  • OBJECTIVE: To determine factors associated with physician discovery of early melanoma in middle-aged and older men.
  • SETTING: Three institutional melanoma clinics.
  • PARTICIPANTS: A total of 227 male participants (aged > or =40 years) with invasive melanoma who completed surveys within 3 months of diagnosis.
  • MAIN OUTCOME MEASURES: Factors associated with physician-detected thin melanoma.
  • RESULTS: Patients with physician-detected melanoma were older, 57% were 65 years or older compared with 34% for other-detected (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.19-5.55) and 42% for patient-detected melanoma (P = .07).
  • Physician-detected melanoma in the oldest patients (aged > or =65 years) had tumor thickness equal to that of self-detected melanoma or melanoma detected by other means in younger patients.
  • Back lesions composed 46% of all physician-detected melanoma, 57% of those detected by other means, and 16% of self-detected lesions (physician- vs self-detected: OR, 4.25; 95% CI, 1.96-9.23).
  • Ninety-two percent of all physician-detected back-of-the-body melanomas were smaller than 2 mm compared with 63% of self-detected lesions (P = .004) and 76% of lesions detected by other means (P = .07).
  • CONCLUSIONS: Skin screenings of at-risk middle-aged and older American men can be integrated into the routine physical examination, with particular emphasis on hard-to-see areas, such as the back of the body.
  • "Watch your back" professional education campaigns should be promoted by skin cancer advocacy organizations.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Dermatology. Early Diagnosis. Humans. Male. Middle Aged. Patient Education as Topic. Physicians. Self Care

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2009 Apr 22;301(16):1702-4 [19388140.001]
  • (PMID = 19380662.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Janda M, Lowe JB, Elwood M, Ring IT, Youl PH, Aitken JF: Do centralised skin screening clinics increase participation in melanoma screening (Australia)? Cancer Causes Control; 2006 Mar;17(2):161-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do centralised skin screening clinics increase participation in melanoma screening (Australia)?
  • OBJECTIVE: To compare during the first 12 months of a 3-year randomised community-based trial of population screening for melanoma three methods of screening delivery: skin screening within day-to-day primary care (Group A); screening in dedicated skin screening clinics either organised privately by local physicians (Group B); or organised centrally with participants referred back to their physicians for definitive diagnosis and management (Group C).
  • The self-reported prevalence of clinical skin examination was assessed by surveying 3,110 residents (66.9% participation rate) aged > or = 30 years by telephone at baseline, and 14,060 residents (70.9% participation rate) by self-administered mailed questionnaire at 12-month follow-up.
  • RESULTS: At baseline the prevalence of skin screening did not differ between intervention and control communities.
  • At 12-month follow-up, participants within intervention communities reported skin screening significantly more frequently (20.9% versus 10.9%; p < 0.001).
  • Within intervention communities, the prevalence of clinical skin examinations in Group A was similar to that of control communities (12.6% and 10.9%; p = 0.33).
  • CONCLUSIONS: The provision of centrally organised skin screening clinics significantly increases skin screening rates and may have relevance for future melanoma control programmes.
  • [MeSH-major] Ambulatory Care Facilities / statistics & numerical data. Melanoma / epidemiology. Primary Health Care / statistics & numerical data. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425094.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, Wheelhouse C: The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med (Lond); 2007 Jun;7(3):283-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines.
  • Melanoma of the skin is an increasingly common tumour, which often has a slow early growth rate during which curable lesions may be detected and removed.
  • Physicians therefore have the potential to reduce mortality and this guideline is intended to promote early diagnosis of melanoma.
  • The most common risk factors are pale sun-sensitive skin and the presence of increased numbers of melanocytic naevi (moles).
  • Melanoma is more common in women than men; the mean age of onset is 50 years; and a fifth of cases occur in young adults.
  • In the UK population the most common sites are on the lower leg in women, and on the back in men.
  • The predictors of melanoma are progressive change in the shape, size and colour of moles.
  • This guideline provides a series of photographs of moles, melanomas and other skin lesions, which may resemble melanomas.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633952.001).
  • [ISSN] 1470-2118
  • [Journal-full-title] Clinical medicine (London, England)
  • [ISO-abbreviation] Clin Med (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


34. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev; 2007 May;16(5):991-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
  • Malignant melanomas often contain BRAF or NRAS mutations, but the relationship of these mutations to ambient UV exposure in combination with phenotypic characteristics is unknown.
  • In a population-based case series from North Carolina, 214 first primary invasive melanoma patients in the year 2000 were interviewed regarding their risk factors.
  • Mutually exclusive BRAF-mutant and NRAS-mutant cases occurred at frequencies of 43.0% and 13.6% with mean ages at diagnosis of 47.3 and 62.1 years, respectively.
  • Tumors from patients with >14 back nevi were more likely to harbor either a BRAF mutation [age-adjusted odds ratio (OR), 3.2; 95% confidence interval (95% CI), 1.4-7.0] or an NRAS mutation (age-adjusted OR, 1.7; 95% CI, 0.6-4.8) compared with patients with 0 to 4 back nevi.
  • The association of BRAF mutations with early-life UV exposure provides evidence in support of childhood sun protection for melanoma prevention.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507627.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Databank-accession-numbers] RefSeq/ NM/ 002524/ NM/ 004333
  • [Grant] United States / NCI NIH HHS / CA / R03 CA103089; United States / NCI NIH HHS / CA / R03 CA103089-02; United States / NCI NIH HHS / CA / CA83180; United States / NCI NIH HHS / CA / R01 CA112524; United States / NCI NIH HHS / CA / K07 CA102096-05; United States / NCI NIH HHS / CA / CA102096; United States / NCI NIH HHS / CA / CA103089; United States / NCI NIH HHS / CA / CA102096-05; United States / NCI NIH HHS / CA / CA103089-02; United States / NCI NIH HHS / CA / K07 CA102096; United States / NCI NIH HHS / CA / CA112243; United States / NCI NIH HHS / CA / R01 CA112243; United States / NCI NIH HHS / CA / R01 CA112243-04; United States / NCI NIH HHS / CA / CA112243-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


35. Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG: Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res; 2005 Mar 1;65(5):2009-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
  • However, expression of other melanoma-associated antigens, such as gp100, was not affected.
  • When transplanted back into syngeneic animals, variants were very poorly controlled by further vaccination.
  • [MeSH-major] Antigens, Neoplasm / immunology. CD8-Positive T-Lymphocytes / immunology. Immunotherapy, Adoptive. Melanocytes / drug effects. Melanoma, Experimental / immunology. Tumor Escape. Vaccines, DNA / immunology
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Combined Modality Therapy. DNA Methylation / drug effects. Interferon-gamma / metabolism. Intramolecular Oxidoreductases / genetics. Intramolecular Oxidoreductases / immunology. Intramolecular Oxidoreductases / metabolism. Membrane Glycoproteins / genetics. Membrane Glycoproteins / immunology. Membrane Glycoproteins / metabolism. Mice. Mice, Inbred C57BL. Mice, Nude. Monophenol Monooxygenase / genetics. Monophenol Monooxygenase / immunology. Monophenol Monooxygenase / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology. Neoplasm Proteins / metabolism. Perforin. Pore Forming Cytotoxic Proteins. Vaccination. gp100 Melanoma Antigen

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753401.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA91956; United States / NCI NIH HHS / CA / R01 CA94180
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antimetabolites, Antineoplastic; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Pore Forming Cytotoxic Proteins; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 126465-35-8 / Perforin; 82115-62-6 / Interferon-gamma; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase; M801H13NRU / Azacitidine
  •  go-up   go-down


36. Zeren-Bilgin I, Gür S, Aydin O, Ermete M: Melanoma arising in a hairy nevus spilus. Int J Dermatol; 2006 Nov;45(11):1362-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma arising in a hairy nevus spilus.
  • Cutaneous melanoma may develop de novo on normal skin or in contiguity with a potential melanocytic precursor.
  • Physical examination revealed a 10x18-cm lesion with speckled lentiginous pigmentation and terminal hairs on the lower back.
  • Histopathological evaluation of the nevus and the suspicious nodule revealed the characteristics of a melanocytic nevus and melanoma, respectively.
  • This case report is a reminder that there may be great variation in the clinical appearance of nevus spilus, and thus dermatologists must be aware of these lesions as potential precursors of malignant melanoma.
  • [MeSH-major] Lentigo / complications. Melanoma / etiology. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076727.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP: Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res; 2005 Apr;15(2):83-9
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin-induced apoptosis in human melanoma cell lines.
  • The cholesterol-lowering medications, statins, inhibit cellular proliferation and induce apoptosis in an array of cancer cell lines, including melanoma.
  • We investigated the apoptotic mechanism of lovastatin on human melanoma cell lines in vitro.
  • Farnesyl pyrophosphate and geranylgeranyl pyrophosphate add-back experiments were performed to better define the molecular mechanisms mediating lovastatin cytotoxicity.
  • Lovastatin caused cytotoxicity in human and murine melanoma cells, but did not induce toxicity in an epidermoid carcinoma cell line A431.
  • For human melanoma cells, lovastatin precipitated cell rounding, increased the percentage of apoptotic cells detected by ethidium bromide and acridine orange staining and by the Annexin V apoptosis detection kit, and resulted in a 50-fold increase in active caspase 3, corroborating that lovastatin induced apoptosis.
  • Adding back geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, reversed the effects of lovastatin in A375 cells.
  • Of the five statins tested, pravastatin was least effective in killing melanoma cells.
  • Lovastatin induced caspase-dependent apoptosis in multiple melanoma cell lines via a geranylation-specific mechanism.
  • This study supports a possible role of lovastatin as a therapeutic, adjuvant or chemopreventive agent for melanoma.
  • [MeSH-major] Apoptosis / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Lovastatin / pharmacology. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846140.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K-07 CA92550-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Polyisoprenyl Phosphates; 0 / Sesquiterpenes; 6699-20-3 / geranylgeranyl pyrophosphate; 79W6B01D07 / farnesyl pyrophosphate; 9LHU78OQFD / Lovastatin; EC 2.5.1.1 / Dimethylallyltranstransferase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; KXO2KT9N0G / Pravastatin
  •  go-up   go-down


38. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T: Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun; 2008 Jan 11;365(2):279-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
  • We investigated whether blocking of monocyte chemoattractant-1 (MCP-1) function would inhibit recruitment of tumor-associated macrophages (TAMs) and prevent tumor angiogenesis and tumor growth of human malignant melanoma.
  • B16-F1 melanoma cells were implanted onto the back of C57BL/6 mice (Day 0).
  • Melanoma cells expressed not only MCP-1 but also its receptor CCR2.
  • Accordingly, it was suggested that MCP-1 would enhance tumor angiogenesis and early tumor growth in the early stages by inducing TNFalpha, IL-1alpha, and VEGF through TAM recruitment and probably the direct autocrine/paracrine effects on melanoma cells.
  • [MeSH-major] Chemokine CCL2 / genetics. Genetic Therapy / methods. Melanoma / genetics. Melanoma / therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / prevention & control

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991428.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2
  •  go-up   go-down


39. Buljan M, Situm M, Tomas D, Cavka V, Poduje S, Gasparov S: A case report of an unrecognized nevoid melanoma in a young woman--clinicopathological diagnostic challenge. Coll Antropol; 2010 Apr;34 Suppl 2:307-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of an unrecognized nevoid melanoma in a young woman--clinicopathological diagnostic challenge.
  • Nevoid melanoma is a rare form of melanoma histologically resembling benign melanocytic nevi and may be overlooked in routine histological sections.
  • Authors are presenting a case of a 31-year-old woman who presented with bizarre pigmented skin lesions in the area of the postoperative scar on the back where, 6 years earlier, a "nevus pigmentosus epidermo-dermalis" was excised and hystologically confirmed in outer institution.
  • The lesions were surgically removed and histopathological findings were characteristic for nevoid melanoma.
  • Additionally, specimen of primary removed lesion was reexamined and primary nevoid melanoma was then recognized, therefore indicating that the lesions our patient presented with are nevoid melanoma recidivisms.
  • Extensive diagnostic procedures showed no signs of melanoma dissemination.
  • The lesions were excised and new nevoid melanoma recidivism was confirmed.
  • The patient remained under the regular follow up and, almost 9 years after the removal of primary nevoid melanoma, followed by two cutaneous recidivisms, remains disease-free.
  • This case aims to highlight the problematic area in the analysis of pigmented skin lesions where nevoid melanoma represents one of the clinical and pathological diagnostic challenges.
  • [MeSH-major] Melanoma / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21305748.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  •  go-up   go-down


40. Stante M, de Giorgi V, Carli P: Possible role of dermoscopy in the detection of a primary cutaneous melanoma of unknown origin. J Eur Acad Dermatol Venereol; 2006 Mar;20(3):299-302
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible role of dermoscopy in the detection of a primary cutaneous melanoma of unknown origin.
  • For 2-8% of patients with metastatic melanoma, cutaneous and mucosal clinical examination does not lead to diagnosis of the primary tumour, which remains unknown.
  • We report the case of a 41-year-old male patient who had received a diagnosis of metastatic melanoma after histological examination of an enlarged axillary lymph node, without previous detection of the primary lesion at his first dermatological examination.
  • No pigmented skin lesions located in the anatomical area potentially drained by the affected axillary basin showed clinical features suggestive of a melanoma.
  • Neither did the so-called 'ugly duckling' sign help us to identify the melanoma, because of the presence of a large number of clinically similar, common or slightly atypical melanocytic lesions located in that area.
  • Histological examination revealed the primary melanoma (superficial spreading melanoma (SSM), level III, thickness 0.5 mm)--located on the back--and three naevi with atypia.
  • Preoperative distinction of the melanoma from the other three lesions was not possible because of the lack of well-established features of malignancy, even at dermoscopic analysis ('featureless' melanoma).
  • Dermoscopy may thus play a role in the detection of a clinically unknown primary melanoma by narrowing the field of lesions to be removed for histological examination, saving many unnecessary excisions that would otherwise be inevitable.
  • [MeSH-major] Melanoma / diagnosis. Neoplasms, Unknown Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Axilla / pathology. Back / pathology. Dermoscopy. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503891.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Kudriavtsev DV, Mardynskiĭ IuS, Kudriavtseva GT: [Gender, tumor localization and regional metastases as prognostic factors in combined and complex treatment of cutaneous melanoma]. Vopr Onkol; 2007;53(2):170-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gender, tumor localization and regional metastases as prognostic factors in combined and complex treatment of cutaneous melanoma].
  • Data on 373 patients treated for cutaneous melanoma were evaluated to test a hypothesis whether there is a correlation between mechanism of protection from ultraviolet radiation and gender.
  • Cutaneous melanoma of the extremities was identified in 63.2% of females and 26.6% of males (p<0.001) versus 26.1% and 54.0%, respectively, with tumors of the trunk (p<0.001).
  • [MeSH-major] Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Abdomen. Adult. Back. Extremities. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663170.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


42. Banaczek Z, Ruka W, Bator M, Krzyszkowska I: [Cutaneous melanoma during pregnancy--a case report]. Przegl Lek; 2006;63(3):169-70
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous melanoma during pregnancy--a case report].
  • Cutaneous melanoma is a tumour which has the highest increase of incidence per year.
  • In this essay, a case of cutaneus melanoma co-existing with pregnancy was presented.
  • An excision biopsy of the skin lesion on the back surface of the left shank was carried out.
  • III degree melanoma malignum according to Clark's, and 1,6 mm according to Breslov was diagnosed.
  • The accurate evaluation of the pigmented nevus appearance could contribute to the diagnosis of the melanoma in the early stage of progression.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / surgery. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967705.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


43. Purdue MP, From L, Kahn HJ, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD: Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma. Int J Cancer; 2005 Nov 10;117(3):486-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma.
  • Findings from a case-control study of cutaneous malignant melanoma (CMM) in Queensland, Australia, suggest that melanomas exhibiting p53 immunostaining possess different risk factors from those of other melanomas.
  • The presence of strong p53 staining (>10% of cell nuclei positively stained vs. <1% staining) was positively associated with some indicators of high cumulative sun exposure: lentigo maligna melanoma subtype (OR = 3.2 vs. superficial spreading subtype), melanoma location on the head and neck (OR = 2.8 vs. back), histopathologic evidence of solar elastosis (OR = 2.1) and previous diagnosis of nonmelanoma skin cancer (OR = 2.4).
  • Strong staining was negatively associated with high nevus density on the back (OR = 0.2 for >25 nevi vs. 0-3 nevi) and histologic evidence of a coexisting nevus (OR = 0.3).
  • Of these, thickness, male sex, dense freckling, low nevus density on the back, histologic subtype and history of nonmelanoma skin cancer appeared to be independently associated with strong p53 staining.
  • Our findings are consistent with the Queensland study in suggesting that variables indicating high accumulated sun exposure are positively associated with p53 staining and that an increased number of nevi is positively associated with its absence; they may reflect etiologic and pathogenetic heterogeneity in melanoma.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900597.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA103394; United States / NCI NIH HHS / CA / U01 CA083180
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


44. Khan O, Middleton M: High-risk melanoma with nodal involvement in a young woman. Nat Clin Pract Oncol; 2006 Sep;3(9):517-21; quiz 522
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk melanoma with nodal involvement in a young woman.
  • BACKGROUND: An 18-year-old female presented to her General Practitioner with a bleeding mole on her back.
  • Physical examination revealed a 1.5 cm 1.7 cm pigmented lesion on the left aspect of the patient's upper back.
  • DIAGNOSIS: Stage IIIB (T3bN2aM0) focally ulcerated, nodular malignant melanoma (Breslow depth 2.5 mm, Clark's level IV).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Lymph Nodes / pathology. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955090.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


45. Dal H, Boldemann C, Lindelöf B: Does relative melanoma distribution by body site 1960-2004 reflect changes in intermittent exposure and intentional tanning in the Swedish population? Eur J Dermatol; 2007 Sep-Oct;17(5):428-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does relative melanoma distribution by body site 1960-2004 reflect changes in intermittent exposure and intentional tanning in the Swedish population?
  • Intermittent exposure to UV-radiation at an early age is a known important factor in the aetiology of malignant melanoma.
  • We surveyed data from the Swedish Cancer Registry for melanoma by body site for age and gender cohorts from 1960 to 2004, in an attempt to discern a reflection of major behavioural and societal changes in the relative distribution of melanoma by body site.
  • The study comprised patients with malignant melanoma from the Swedish Cancer Registry, including information on body site of tumour (January 1, 1960 - December 31, 2004).
  • In total, 46,337 malignant melanomas were diagnosed in 44,623 patients.
  • This supports the hypothesis of a relationship between intentional exposure to ultraviolet radiation and malignant melanoma.
  • [MeSH-major] Environmental Exposure. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Sunlight / adverse effects
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Back / pathology. Child. Child, Preschool. Extremities / pathology. Female. Head / pathology. Humans. Incidence. Infant. Male. Middle Aged. Recreation. Registries. Sex Factors. Sweden / epidemiology. Thorax / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673388.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Drugge RJ, Nguyen C, Drugge ED, Gliga L, Broderick PA, McClain SA, Brown CC: Melanoma screening with serial whole body photographic change detection using Melanoscan technology. Dermatol Online J; 2009;15(6):1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma screening with serial whole body photographic change detection using Melanoscan technology.
  • The use of an automated, whole-body, diffusely lit digital imaging enclosure to produce serial images, which were then compared, using an astrophysics image display method, enabled a private practice dermatologist to detect melanoma at significantly thinner Breslow depths compared to all other clinical detection paradigms examined in this study.
  • The patients were triaged to scanning using a melanoma risk survey system.
  • The system employed a 24 camera semicircular imaging wall, with front and back views.
  • Image to image comparison of whole body digital photography was combined with a whole body skin exam in order to sensitize a clinical dermatologist to skin changes in individuals at risk for melanoma.
  • Mean depths (Breslow scores) were compiled from six distinct melanoma biopsy cohorts segregated and based on different clinical screening paradigms.
  • This approach provides a quick and effective method for detection of early melanomas with a significant reduction in the skin area required for lesion examination.
  • [MeSH-major] Melanoma / pathology. Photography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723475.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Lewis TJ: Toxicity and cytopathogenic properties toward human melanoma cells of activated cancer therapeutics in zebra fish. Integr Cancer Ther; 2010 Mar;9(1):84-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and cytopathogenic properties toward human melanoma cells of activated cancer therapeutics in zebra fish.
  • PDT is a well-known activated therapy with roots dating back to 1900.
  • In the cytotoxicity studies, melanoma cell line WM-266-4, derived from a metastatic site of a malignant melanoma, was tested against SF1 and SF2.
  • Both sensitizer systems showed marked efficacy in the destruction of the implanted melanoma cells.
  • [MeSH-major] Apoptosis. Melanoma / pathology. Melanoma / therapy. Photochemotherapy. Ultrasonic Therapy. Zebrafish

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308086.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents
  •  go-up   go-down


48. De Giorgi V, Pinzani P, Salvianti F, Grazzini M, Orlando C, Lotti T, Pazzagli M, Massi D: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol; 2010 Oct;146(10):1120-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis.
  • BACKGROUND: The notion that only malignant melanoma cells circulate and diffuse is shared by oncologists and pathologists.
  • OBSERVATIONS: During a study of identification of circulating melanoma cells using ISET, blood samples from a 69-year-old man with an atypical melanocytic lesion on his back were evaluated.
  • The morphological features were similar to those of the excised skin tissue specimen, and the patient was subsequently diagnosed as having a congenital melanocytic nevus.
  • CONCLUSION: The finding that benign nevus cells may circulate in blood brings into question the value of tyrosinase or other melanocytic markers as a molecular surrogate for circulating melanoma cells.
  • [MeSH-major] Cell Separation / methods. Melanoma / secondary. Molecular Diagnostic Techniques / methods. Neoplastic Cells, Circulating. Skin Neoplasms / pathology


49. Kakutani K, Doita M, Nishida K, Miyamoto H, Kurosaka M: Radiculopathy due to malignant melanoma in the sacrum with unknown primary site. Eur Spine J; 2008 Sep;17 Suppl 2:S271-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.
  • Melanoma is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.
  • To report a very rare case of malignant melanoma in the sacrum with unknown primary origin.
  • The authors present a case of a 52-year-old man who was admitted with increasing lower back, left buttock, and left lower extremity pain, and dysuria.
  • The pathological diagnosis was malignant melanoma.
  • No obvious primary malignant melanoma was detected on the skin surface, on the oral or anal mucosa, or in the fundus oculi.
  • However the patient died nine months after initial diagnosis.
  • Malignant melanoma in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.
  • The melanoma could have been a metastatic tumor of the sacrum, although the primary site was not detected.
  • The incidence of primary melanoma is increasing faster than any other cancer.
  • Thus treatment of patients with spinal metastasis of melanoma is an important challenge for orthopedic surgeons.
  • [MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Back Pain / etiology. Back Pain / pathology. Back Pain / physiopathology. Disease Progression. Drug Therapy. Fatal Outcome. Humans. Ilium / pathology. Ilium / radiography. Magnetic Resonance Imaging. Male. Middle Aged. Polyradiculopathy / etiology. Polyradiculopathy / pathology. Polyradiculopathy / physiopathology. Radiotherapy. Sacroiliac Joint / pathology. Sacroiliac Joint / radiography. Spinal Canal / pathology. Spinal Canal / radiography. Tomography, X-Ray Computed. Treatment Failure. Urination Disorders / etiology. Urination Disorders / pathology. Urination Disorders / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):78-80 [10711643.001]
  • [Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]
  • [Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]
  • [Cites] Oncology. 1972;26(2):265-70 [5049921.001]
  • [Cites] Cancer. 1972 Dec;30(6):1469-72 [4641758.001]
  • [Cites] Br J Surg. 1977 Nov;64(11):805-8 [588977.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):98-104 [7352784.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]
  • [Cites] CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26 [2049635.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6 [8588172.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Mar;77(3):307-9 [8600878.001]
  • [Cites] Br J Surg. 1967 Jul;54(7):651-8 [6026989.001]
  • (PMID = 18075762.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2525896
  •  go-up   go-down


50. Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F: Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol; 2007 Apr;18(4):789-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series.
  • BACKGROUND: The relation between detailed cutaneous distribution of melanoma and indicators of sun exposure patterns has scantily been explored in moderately sun-sensitive populations.
  • PATIENTS AND METHODS: The precise site of 1658 primary malignant melanoma, registered from 1995 to 2002, in Switzerland were retrieved and clinically validated.
  • Relative melanoma density (RMD) was computed by the ratio of observed to expected number of melanoma allowing for body site surface areas, and further adjusted for site-specific melanocyte density.
  • RESULTS: Sites of highest risks were the face, shoulder and upper arm for both sexes, the back for men, and leg for women.
  • Major features of this series were: (i) an unexpectedly high RMD for the face in women (5.6 versus 3.7 in men), (ii) the absence of a male predominance for melanoma on the ears and (iii) for the upper limbs, a steady gradient of increasing melanoma density with increasing proximity to the trunk, regardless of sex.
  • CONCLUSION: RMD increased with (cumulative) site sun exposure, but a few notable exceptions support the impact of intermittent exposure in melanoma risk.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237475.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Braun-Falco M, Friedrichson E, Ring J: Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma. Hum Pathol; 2005 Apr;36(4):412-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma.
  • Cleft formation has been postulated as a clue to the histopathological diagnosis of malignant melanoma (MM).
  • The presence of clefts was not associated with age or sex of the patients, but showed a slight predilection for the back, a slightly higher prevalence in superficial spreading type of MM and for tumors with a Breslow thickness between 1 and 2 mm.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Female. Humans. Male. Nevus, Pigmented / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2006 Jul;37(7):919-20 [16784994.001]
  • [CommentIn] Hum Pathol. 2006 Feb;37(2):246; author reply 247 [16426927.001]
  • (PMID = 15892003.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


52. Katagiri Y, Hozumi Y, Kondo S: Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci; 2006 Jun;42(3):215-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo.
  • BACKGROUND: Low levels of p27Kip1 expression are associated with poor prognosis in various malignancies including malignant melanoma.
  • Recently, it has been reported that S phase kinase-interacting protein 2 (Skp2), the specific ubiquitin ligase subunit that targets p27Kip1 for degradation, was overexpressed and was inversely related to p27Kip1 levels in malignant melanoma with poor prognosis.
  • OBJECTIVE: We investigated whether small interfering RNA (siRNA)-mediated gene silencing of Skp2 can be employed in order to inhibit p27Kip1 down-regulation and suppress melanoma cell growth as a consequence in vitro and in vivo.
  • METHODS: We constructed a plasmid vector, which synthesizes siRNAs to determine the effects of decreasing the high constitutive levels of Skp2 protein in melanoma cells.
  • Furthermore, melanoma cells were injected into the back of nude mice subcutaneously to examine the suppression of tumorigenicity targeting Skp2 gene silencing in vivo.
  • RESULTS: Skp2 protein was decreased and the p27Kip1 protein was accumulated in Skp2 siRNA transfected melanoma cells.
  • Skp2 siRNA inhibited the cell growth of melanoma cells in vitro.
  • CONCLUSION: Our results suggest that siRNA-mediated gene silencing of Skp2 can be a potent tool of cancer gene therapy for suppression of p27Kip1 degradation in malignant melanoma.
  • [MeSH-major] Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p27 / drug effects. Melanoma / drug therapy. RNA, Small Interfering / therapeutic use. S-Phase Kinase-Associated Proteins / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor. Down-Regulation / drug effects. Gene Expression Regulation, Neoplastic. Humans. Leupeptins. Melanoma, Experimental. Mice. Mice, Nude. RNA Interference

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504485.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Leupeptins; 0 / RNA, Small Interfering; 0 / S-Phase Kinase-Associated Proteins; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


53. Ghosh A, Pradhan S, Swami R, Kc SR, Talwar O: Primary malignant melanoma of vagina--a case report with review of literature. JNMA J Nepal Med Assoc; 2007 Oct-Dec;46(168):203-5
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of vagina--a case report with review of literature.
  • Primary vaginal malignant melanoma is a very rare tumor with less than 300 cases reported to date.
  • We describe a case of primary vaginal melanoma and review the literature.
  • Histopathology of the mass showed features of malignant melanoma.
  • However patient came back after three months with widespread metastasis and expired 6 months after the initial diagnosis.
  • Vaginal melanoma is a very aggressive tumor and the overall prognosis is very poor despite the treatment modality.
  • [MeSH-major] Melanoma / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Combined Modality Therapy / methods. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340375.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


54. Corrigan MA, Coffey JC, O'Sullivan MJ, Fogarty KM, Redmond HP: Sentinel lymph node biopsy: is it possible to reduce false negative rates by excluding patients with nodular melanoma? Surgeon; 2006 Jun;4(3):153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy: is it possible to reduce false negative rates by excluding patients with nodular melanoma?
  • OBJECTIVE: The aim of this study was to review the outcome of sentinel lymph node biopsy (SLNB) in patients with melanoma and to delineate whether patients with nodular melanoma are more likely to develop nodal recurrence despite negative SLNB.
  • METHODS: Consecutive patients with cutaneous melanoma undergoing SLNB were identified from a departmental database between 1997 and 2005.
  • Primary melanoma sites included lower limb (49; 48%), upper limb (29; 28%), head (12; 11%), trunk (7; 7%) and back (6; 6%).
  • Superficial spreading accounted for 43% of melanoma with nodular accounting for 42%.
  • All of the three patients with satellite lesions had nodular melanoma histologically (p=0.02).
  • CONCLUSIONS: This study indicates that lymphatic recurrence occurs more often in SLNB negative patients with nodular melanoma.
  • [MeSH-major] Melanoma / secondary. Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nodular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgeon. 2007 Oct;5(5):320 [17960716.001]
  • (PMID = 16764200.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


55. Hershkovitz L, Schachter J, Treves AJ, Besser MJ: Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol; 2010;2010:260267
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focus on adoptive T cell transfer trials in melanoma.
  • Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%-70% of the patients.
  • It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient.
  • [MeSH-major] Immunotherapy, Adoptive / methods. Lymphocytes, Tumor-Infiltrating / transplantation. Melanoma / therapy. T-Lymphocytes / transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1984 Sep 28;225(4669):1487-9 [6332379.001]
  • [Cites] N Engl J Med. 1985 Dec 5;313(23):1485-92 [3903508.001]
  • [Cites] JAMA. 1986 Dec 12;256(22):3117-24 [3491225.001]
  • [Cites] J Immunol Methods. 1987 Aug 3;101(2):171-81 [3611795.001]
  • [Cites] J Immunol Methods. 1987 Dec 24;105(2):183-92 [3693906.001]
  • [Cites] N Engl J Med. 1988 Dec 22;319(25):1676-80 [3264384.001]
  • [Cites] J Immunol. 1989 May 1;142(9):3329-35 [2785141.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8 [2513569.001]
  • [Cites] N Engl J Med. 1990 Aug 30;323(9):570-8 [2381442.001]
  • [Cites] J Immunol. 1991 May 15;146(10):3674-81 [1902860.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] J Immunother (1991). 1991 Jun;10(3):153-64 [1868040.001]
  • [Cites] J Immunol. 1992 Jan 15;148(2):638-43 [1729379.001]
  • [Cites] J Immunother (1991). 1992 Jul;12(1):1-12 [1637779.001]
  • [Cites] Immunity. 2005 Apr;22(4):403-14 [15845446.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7853-8 [15944290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5763-71 [19884534.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jun;59(6):921-31 [20101507.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):843-51 [20179677.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2646-55 [20406835.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):711-23 [20525992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):18-30 [8435428.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):622-32 [8468720.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1475-83 [8021739.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):833-41 [9120389.001]
  • [Cites] Immunity. 1998 May;8(5):615-23 [9620682.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):307-19 [9742914.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5133-7 [9820481.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7125-30 [15585832.001]
  • [Cites] Blood. 2005 Jan 1;105(1):241-50 [15345595.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4 [10685652.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Mar;19(1):21-34 [10840932.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):449-59 [11191112.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Immunol. 2001 Jul 15;167(2):1090-6 [11441120.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3155-63 [12384413.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):427-45 [12407508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):61-8 [12816983.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):7046-52 [16272366.001]
  • [Cites] Dermatol Ther. 2006 Jan-Feb;19(1):19-25 [16405566.001]
  • [Cites] Isr Med Assoc J. 2006 Mar;8(3):164-8 [16599050.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7726-35 [16751420.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Dec;3(12):668-81 [17139318.001]
  • [Cites] J Immunother. 2007 Jan;30(1):123-9 [17198091.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):492-501 [17273561.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):524-31 [18083376.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Immunol. 2008 May 1;180(9):6116-31 [18424733.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5326-33 [18276844.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3445-55 [18612161.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] J Immunother. 2008 Oct;31(8):742-51 [18779745.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5233-9 [18809613.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):169-80 [19118044.001]
  • [Cites] Cancer J. 2009 Mar-Apr;15(2):150-4 [19390311.001]
  • [Cites] Mol Syst Biol. 2009;5:265 [19401677.001]
  • [Cites] J Immunother. 2009 May;32(4):415-23 [19342963.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Jun;23(3):583-97, x [19464604.001]
  • [Cites] Blood. 2009 Jul 16;114(3):535-46 [19451549.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5852-60 [19737958.001]
  • [Cites] Hum Gene Ther. 2008 Nov;19(11):1219-32 [19848582.001]
  • (PMID = 21234353.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3018069
  •  go-up   go-down


56. Uren RF, Howman-Giles R, Chung DK, Morton RL, Thompson JF: The reproducibility in routine clinical practice of sentinel lymph node identification by pre-operative lymphoscintigraphy in patients with cutaneous melanoma. Ann Surg Oncol; 2007 Feb;14(2):899-905
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reproducibility in routine clinical practice of sentinel lymph node identification by pre-operative lymphoscintigraphy in patients with cutaneous melanoma.
  • Pre-operative lymphoscintigraphy (LS) is an important part of successful sentinel lymph node (SLN) biopsy in most melanoma treatment centers.
  • The test accurately maps lymphatic drainage from cutaneous melanoma sites and has been shown to be reproducible in prospective studies.
  • This has happened on 21 occasions at the Sydney Melanoma Unit and we have performed a retrospective analysis of the reproducibility of the LS results.
  • One showed two extra interval nodes on the back as well as concordant flow to SLNs in each axilla.
  • The other with a leg melanoma showed the same groin SLNs but failed to relabel the two popliteal SLNs on the second study.
  • These results indicate that in routine clinical practice LS is a highly reproducible procedure to locate and radiolabel the SLNs prior to biopsy in patients with melanoma.
  • [MeSH-major] Lymph Nodes / radionuclide imaging. Melanoma / radionuclide imaging. Sentinel Lymph Node Biopsy. Skin Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103064.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


57. Atzeni M, Serratore F, Zaccheddu F, Buosi M, Nemolato S, Ribuffo D: Multiple melanoma arising on a burn scar and extensive sunburn: a case report and a review of the literature. Melanoma Res; 2009 Aug;19(4):195-8
MedlinePlus Health Information. consumer health - Sun Exposure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple melanoma arising on a burn scar and extensive sunburn: a case report and a review of the literature.
  • Melanoma arising in a burn scar is very uncommon.
  • We report a recent case of a female patient in whom two different melanomas arose on a wide back burn scar at different times, focusing attention on three different potential risk factors for melanoma the patient had: sunburns, laser therapy on back and burn scar.
  • [MeSH-major] Burns / pathology. Cicatrix / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Sunburn / pathology
  • [MeSH-minor] Adult. Back. Female. Humans. Joint Diseases / rehabilitation. Laser Therapy. Lentigo. Risk Factors. Skin Transplantation. Smoking. Telangiectasis

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543127.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


58. Eichhoff OM, Zipser MC, Xu M, Weeraratna AT, Mihic D, Dummer R, Hoek KS: The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Res; 2010 Aug;20(4):349-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.
  • To date there is no effective therapy for metastatic melanoma and at the molecular level the disease progression is poorly understood.
  • A recent study by our group led to the development of a novel phenotype switching model for melanoma progression, wherein cells transition back-and-forth between states of proliferation and invasion to drive disease progression.
  • To explore the model's clinical relevance we interrogated phenotype-specific expression patterns in human melanoma patient material.
  • A matched primary/metastasis pair from a human melanoma patient was obtained and immunohistochemically stained for proliferative and invasive phenotype markers.
  • Strikingly, we observed that late phase metastatic melanoma cells adopt morphologies and behaviours identical to very early phase cells.
  • These results highlight the likelihood that disease progression involves melanoma cells retaining the capacity to regulate the expression of metastatic potential critical factors according to changing microenvironmental conditions.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] PLoS Genet. 2009 Mar;5(3):e1000427 [19300477.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):333-43 [12819038.001]
  • [Cites] Histopathology. 2004 Jun;44(6):517-41 [15186267.001]
  • [Cites] Histochemistry. 1981;72(3):433-42 [7298384.001]
  • [Cites] J Clin Pathol. 1990 Sep;43(9):752-7 [2212067.001]
  • [Cites] J Clin Pathol. 1992 Feb;45(2):143-8 [1371777.001]
  • [Cites] Connect Tissue Res. 1993;29(3):171-80 [8222644.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2999-3008 [9108421.001]
  • [Cites] Annu Rev Genet. 2004;38:365-411 [15568981.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):51-65 [16822996.001]
  • [Cites] Pigment Cell Res. 2006 Aug;19(4):290-302 [16827748.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4259-61 [16830389.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3426-39 [17182868.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):246-55 [17384580.001]
  • [Cites] Chemotherapy. 2007;53(4):233-56 [17595539.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):650-6 [18245463.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Dec;21(6):665-76 [19067971.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10205-14 [19074888.001]
  • [Cites] Dev Biol. 2009 Feb 15;326(2):285-94 [19100728.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • (PMID = 20526217.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA AG000449-02
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS212573; NLM/ PMC2901773
  •  go-up   go-down


59. Falconieri G, Luzar B, Angione V, DeMaglio G, Pizzolitto S: Primary cutaneous nevoid melanoma with Homer-wright rosettes: a hitherto unrecognized variant with immunohistochemical and ultrastructural study. Am J Dermatopathol; 2010 Aug;32(6):606-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous nevoid melanoma with Homer-wright rosettes: a hitherto unrecognized variant with immunohistochemical and ultrastructural study.
  • We report a case of cutaneous nevoid melanoma manifesting as a growing and pruritic pigmented lesion of the back in a 43-year-old woman.
  • Other features were microscopically consistent with melanoma: irregular tumor cell nesting associated with upward migration of melanocytes and consumption of the epidermal component, lack of maturation, expansile growth pattern, and a tendency to confluence of the dermal nests.
  • [MeSH-major] Melanoma / secondary. Nevus / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20520525.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Repertinger S, Wang J, Adickes E, Sarma DP: Melanoma in-situ arising in seborrheic keratosis: a case report. Cases J; 2008;1(1):263
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma in-situ arising in seborrheic keratosis: a case report.
  • BACKGROUND: Seborrheic keratosis is a very common benign skin tumor in man.
  • Melanoma is rare but is the most dreaded of all malignant skin tumors.
  • A melanoma arising in a seborrheic keratosis is distinctly rare.
  • CASE PRESENTATION: An-86-year-old male with a history of multiple actinic keratoses and seborrheic keratoses of the head and trunk presented with a mid-back skin lesion.
  • We interpreted this lesion as a melanoma in-situ arising within a seborrheic keratosis.
  • We urge that all such lesions be examined by the pathologist to avoid missing another concomitant malignant lesion such as melanoma which needs adequate resection and close follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas J Dermatol. 2006 May;47(2):109-13 [16637806.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 1):831-3 [10775864.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):559-61 [15056152.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):278-82 [8806962.001]
  • (PMID = 18947402.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577645
  •  go-up   go-down


61. Stang A, Pukkala E, Sankila R, Söderman B, Hakulinen T: Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer; 2006 Jul 15;119(2):380-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases.
  • Site-specific analyses of the skin melanoma incidence show marked differences between men and women by site and over time.
  • The aim of our study was to analyze long-term population-based incidence time trends of skin melanoma in Finland over a period of more than 50 years, with special emphasis on sex- and subsite-specific changes over time.
  • From 1953 through 2003, the incidence of skin melanoma increased from 1.5 to 12.8 per 100,000 among men and from 1.8 to 10.4 per 100,000 among women.
  • Within the skin area of the head, melanoma of the ear showed the highest relative increase among both men and women.
  • Only skin melanoma of the head showed an exponential age-specific incidence pattern and the aetiology of these skin melanomas may differ from skin melanoma on other subsites.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Arm. Back. Female. Finland / epidemiology. Head. Hip. Humans. Incidence. Leg. Male. Middle Aged. Sex Distribution. Sex Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477634.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CASE REPORT: An 84-year-old white man with a pigmented tumor on the back showing a combination of MM and BCC.
  • RESULTS: A 1.5 x 1.5-cm irregular brown lesion on the back was clinically suggestive of MM.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Cho EA, Lee MA, Kang H, Lee SD, Kim HO, Park YM: Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin. Ann Dermatol; 2009 May;21(2):178-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.
  • Although malignant melanoma usually occurs after the diagnosis of vitiligo-like depigmentation, the latter is rarely followed by the former.
  • We herein report on such a case in which recognition of the vitiligo-like depigmentation preceded diagnosing the metastatic melanoma by several months.
  • A 56-year-old woman had first developed vitiligo-like depigmentation on the forehead, eyelids, neck and back 18 months previously and thereafter she detected a hard mass in the left axilla 2 months previously.
  • Based on the histologic findings, the axillary mass was diagnosed as metastatic melanoma.
  • Our case suggests that the vitiligo-like depigmentation could be a sign that heralds metastatic melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1464-70 [11886510.001]
  • [Cites] Cancer Immunol Immunother. 1996 Jun;42(5):263-7 [8706046.001]
  • [Cites] Ann Dermatol Venereol. 1978 Dec;105(12):1043-52 [753117.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1135-7 [16987274.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):696-708 [6643768.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):314-8 [7887661.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1637-44 [11104805.001]
  • [Cites] Int J Dermatol. 2006 Aug;45(8):952-6 [16911383.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Clin Exp Dermatol. 1991 Jul;16(4):303-5 [1794178.001]
  • [Cites] Dermatologica. 1991;183(4):239-45 [1809584.001]
  • [Cites] Surgery. 1974 Apr;75(4):477-86 [4131002.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):689-96 [6643767.001]
  • [Cites] Pigment Cell Res. 1995 Feb;8(1):60-3 [7792256.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jun;38(6):411-6 [8205563.001]
  • [Cites] Arch Dermatol. 1987 Aug;123(8):1053-5 [3631983.001]
  • (PMID = 20523781.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2861199
  • [Keywords] NOTNLM ; Metastatic melanoma / Vitiligo-like depigmentation
  •  go-up   go-down


64. Eberle FC, Schippert W, Trilling B, Röcken M, Breuninger H: Cosmetic results of histographically controlled excision of non-melanoma skin cancer in the head and neck region. J Dtsch Dermatol Ges; 2005 Feb;3(2):109-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cosmetic results of histographically controlled excision of non-melanoma skin cancer in the head and neck region.
  • BACKGROUND: Beside the primary goal of complete eradication, the cosmetic result is an important aspect of the treatment of non-melanoma skin tumors especially in the head and neck region.
  • RESULTS: Of the 5,565 follow-up questionnaires sent back, 4,868 contained answers regarding the cosmetic result.
  • CONCLUSION: With respect to both long term safety and cosmetic outcome, tumor surgery with 3D-histology of excisional margins has set very high quality standards in the treatment of non-melanoma skin cancer of the head and neck area.
  • [MeSH-major] Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Mohs Surgery / statistics & numerical data. Patient Satisfaction / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery. Surgery, Plastic / statistics & numerical data
  • [MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Germany / epidemiology. Humans. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351013.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Lykke J, Hansen MB, Ovesen H, Meisner S: [Capsule endoscopy detection of metastasis of a malignant melanoma in the small intestine]. Ugeskr Laeger; 2006 Oct 9;168(41):3533-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Capsule endoscopy detection of metastasis of a malignant melanoma in the small intestine].
  • We report a case of a 74-year-old man with a Clark's level II, 2.5 mm melanoma on his back that was excised.
  • Histological diagnosis showed metastatic malignant melanoma.
  • We believe that video capsule endoscopy may increase the rate of diagnosis of small-bowel melanoma metastases.
  • [MeSH-major] Endoscopy, Gastrointestinal. Intestinal Neoplasms / secondary. Melanoma / secondary
  • [MeSH-minor] Aged. Capsules. Gastrointestinal Hemorrhage / diagnosis. Humans. Intestine, Small / pathology. Male. Skin Neoplasms / pathology. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059809.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


66. Derancourt C, Bourdon-Lanoy E, Grob JJ, Guillaume JC, Bernard P, Bastuji-Garin S: Multiple large solar lentigos on the upper back as clinical markers of past severe sunburn: a case-control study. Dermatology; 2007;214(1):25-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple large solar lentigos on the upper back as clinical markers of past severe sunburn: a case-control study.
  • BACKGROUND: Multiple solar lentigos commonly seen on the upper back and shoulders of adults are classically considered as a sign of photodamage, although epidemiological studies are scarce.
  • Past episodes of moderate and severe sunburn were compared between 145 adult patients with multiple solar lentigos on the upper back and 145 matched controls.
  • CONCLUSION: Multiple solar lentigos on the upper back and shoulders of adults are potential clinical markers of past severe sunburn which may thus be used to identify a population at higher risk of developing cutaneous malignant melanoma.
  • [MeSH-minor] Adolescent. Adult. Back. Case-Control Studies. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Odds Ratio. Prognosis. Prospective Studies. Risk Factors. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191044.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M: Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett; 2009 Oct 8;283(2):222-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
  • Currently clinical outcome in melanoma is not predictable by known serum biomarkers.
  • The only reliable tool for the diagnosis of this tumor is the histopathological assay after surgical removing.
  • We used a proteomic approach in order to identify novel non-invasive serum biomarkers of melanoma.
  • Significant increases of expression were found for transthyretin (TTR) and angiotensinogen (AGT) while vitamin D binding protein (DBP) expression was decreased in presence of melanoma.
  • Interestingly, protein expression came back to control values in stages I and II of the disease after 1 month since surgical removal of suspected melanoma.
  • In fact cancer cells release the alpha-N-acetylgalactosaminidase that can deglycosylate DBP thus interfering with the immune cascade response in which DBP is involved, leading to immunosuppression in melanoma patients.
  • Specific enzymatic activity of serum alpha-N-acetylgalactosaminidase was significantly increased in stage III melanoma patients, but not in early stages.
  • This enzymatic assay may provide a non-invasive way of evaluation of melanoma severity.
  • [MeSH-major] Biomarkers, Tumor / blood. Melanoma / blood. Skin Neoplasms / blood. alpha-N-Acetylgalactosaminidase / blood

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394758.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.2.1.49 / alpha-N-Acetylgalactosaminidase
  •  go-up   go-down


68. Oppitz M, Busch C, Schriek G, Metzger M, Just L, Drews U: Non-malignant migration of B16 mouse melanoma cells in the neural crest and invasive growth in the eye cup of the chick embryo. Melanoma Res; 2007 Feb;17(1):17-30
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-malignant migration of B16 mouse melanoma cells in the neural crest and invasive growth in the eye cup of the chick embryo.
  • In a previous study, we observed that human SK-Mel 28 human melanoma cells resumed neural crest cell migration after transplantation into the chick embryo neural tube.
  • Here, we used transgenic mouse B16-F1 melanoma cells transfected with green fluorescent protein-vasodilator-stimulated phosphoprotein construct to extend these observations.
  • After the injection of a cell suspension into the trunk neural tube of E2 chick embryos, the migration of melanoma cells was followed by live fluorescence microscopy.
  • Within 12 h, the melanoma cells formed clusters in the neural tube at the levels of the intersegmental clefts between somites.
  • Emigrated melanoma cells were identified in serial paraffin sections by immunohistochemistry with ab732 as a marker for melanoma cells and by in-situ hybridization of mouse-specific repetitive genomic sequence mL1.
  • After 24 h, melanoma cells were found along the medial neural crest pathway and in the sympathetic trunk ganglia and, after 48 h, also in the lateral melanocytic pathway.
  • During migration along the neural crest pathways, mouse melanoma cells underwent apoptosis, which was assessed by anti-caspase 3 and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling staining.
  • To prove the ablation of malignant behavior after back-transplantation into the original embryonic neural crest environment, we injected the same cell suspension into the eye cup of the E3 embryo.
  • [MeSH-major] Melanoma / pathology. Neural Crest / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235238.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


69. Vazmitel M, Michal M, Mukensnabl P, Kazakov DV: Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion. Am J Dermatopathol; 2007 Dec;29(6):566-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion.
  • We present two cases of melanoma arising in a dysplastic nevus that contained intradermal sebocyte-like melanocytes characterized by a scalloped dark-staining nucleus surrounded by the pale multivacuolated cytoplasm imitating sebaceous differentiation.
  • Location included the back and temporal area.
  • Microscopically, both cases had the following features in common: the melanoma in situ, which was of the superficially spreading type, was associated with a dysplastic compound nevus, in which the sebocyte-like cells were identified in the intradermal nevus part of the lesion.
  • [MeSH-major] Dysplastic Nevus Syndrome / pathology. Melanocytes / pathology. Melanoma / pathology. Sebum / cytology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032954.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


70. Chan YC, Giam YC: A retrospective cohort study of Southeast Asian patients with large congenital melanocytic nevi and the risk of melanoma development. J Am Acad Dermatol; 2006 May;54(5):778-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective cohort study of Southeast Asian patients with large congenital melanocytic nevi and the risk of melanoma development.
  • BACKGROUND: The lifetime risk of developing melanoma in Caucasian patients with large congenital melanocytic nevi (LCMN) is estimated to be between 4.5% and 10%.
  • Cohort studies of LCMN and the risk of melanoma development in an Asian population are not available.
  • OBJECTIVE: We sought to determine the risk of melanoma development in a retrospective cohort of patients presenting with LCMN to a dermatology tertiary referral center in Singapore from January 1989 to December 2004.
  • The most common sites were the back (54%), lower limb (28%), and abdomen (26%).
  • Magnetic resonance imaging of the head or thoracolumbar spine was performed in 7 patients with LCMN on the scalp/face or back, respectively; all produced normal findings.
  • Skin biopsies were done in 5 patients who had developed nodules; histology showed no evidence of malignancy.
  • The small sample size did not allow a precise estimate of the risk of melanoma development in our study population.
  • CONCLUSION: The risk of melanoma development in LCMN within a predominantly Southeast Asian cohort appears to be very low.
  • Hence, patient education, regular melanoma surveillance, and biopsy of suspicious lesions are very important.
  • [MeSH-major] Melanoma / etiology. Nevus, Pigmented / complications. Nevus, Pigmented / congenital. Skin Neoplasms / etiology


71. Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, Kirkpatrick C, Mack T, Bishop JN, Østerlind A, Swerdlow AJ, Zanetti R, Green AC, Karagas MR, Whiteman DC: Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer; 2009 Feb 15;124(4):937-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.
  • A "divergent pathway" model for the development of cutaneous melanoma has been proposed.
  • In contrast, people with an inherent propensity to develop nevi will tend to develop melanomas most often on body sites with large melanocyte populations, such as on the back.
  • We conducted a collaborative analysis to test this hypothesis using the original data from 10 case-control studies of melanoma in women (2,406 cases and 3,119 controls), with assessment of the potential confounding effects of socioeconomic, pigmentary and sun exposure-related factors.
  • Higher nevus count on the arm was associated specifically with an increased risk of melanoma of the trunk (p for trend = 0.0004) and limbs (both upper and lower limb p for trends = 0.01), but not of the head and neck (p for trend = 0.25).
  • The pooled odds ratios for the highest quartile of nonzero nevus count versus none were 4.6 (95% confidence interval (CI) 2.7-7.6) for melanoma of the trunk, 2.0 (95% CI 0.9-4.5) for the head and neck, 4.2 (95% CI 2.3-7.5) for the upper limbs and 3.4 (95% CI 1.5-7.9) for the lower limbs.
  • Aggregate data from these studies suggest that high nevus counts are strongly associated with melanoma of the trunk but less so if at all of the head and neck.
  • This finding supports different etiologic pathways of melanoma development by anatomic site.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / epidemiology. Nevus, Pigmented / diagnosis. Nevus, Pigmented / epidemiology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):231-5 [9219825.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1555-9 [3087514.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):8-12 [9724086.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):276-80 [9766557.001]
  • [Cites] Int J Epidemiol. 1998 Oct;27(5):751-7 [9839729.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):627-32 [10699940.001]
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):416-23 [10869312.001]
  • [Cites] J Am Acad Dermatol. 1999 Apr;40(4):549-57 [10188672.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):457-62 [10233266.001]
  • [Cites] Am J Hum Genet. 1999 Aug;65(2):483-92 [10417291.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2003-5 [15598754.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4 [15894679.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):486-93 [15900597.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):175-82 [16567973.001]
  • [Cites] J Invest Dermatol. 2006 Sep;126(9):2106-10 [16645584.001]
  • [Cites] Cancer Causes Control. 2007 Jun;18(5):485-91 [17450418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7 [17507627.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1100-8 [17990316.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1340-2 [18408748.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):741-50 [11065011.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):69-82 [11227927.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):348-52 [11511314.001]
  • [Cites] Nature. 2001 Sep 20;413(6853):271-2 [11565020.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1085-92 [11953854.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):367-75 [12637916.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):806-12 [12783935.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1765-70 [14578177.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90 [14679157.001]
  • [Cites] Br J Dermatol. 1988 May;118(5):641-4 [3395562.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):821-4 [3192324.001]
  • [Cites] Pigment Cell Res. 1988;1(6):397-401 [3237607.001]
  • [Cites] J Invest Dermatol. 1989 Apr;92(4):561-4 [2703724.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 21;81(12):948-52 [2733040.001]
  • [Cites] Int J Epidemiol. 1990 Dec;19(4):801-10 [2084006.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):920-6 [1607409.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):232-6 [8425760.001]
  • [Cites] Am J Epidemiol. 1994 May 1;139(9):869-80 [8166137.001]
  • [Cites] Am J Epidemiol. 1995 May 15;141(10):943-50 [7741124.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):367-76 [7635560.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):377-81 [7635561.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):393-7 [7635564.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):923-36; quiz 937-40 [7490362.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):1000-7 [7490345.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):636-43 [8782651.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):423-8 [15009725.001]
  • [Cites] Br J Cancer. 1977 Dec;36(6):804-9 [597478.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):257-66 [6582314.001]
  • [Cites] Med J Aust. 1985 Apr 15;142(8):446-8 [3982348.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):843-8 [9714052.001]
  • (PMID = 19035450.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23927; United States / NIEHS NIH HHS / ES / P30 ES007048; United Kingdom / Cancer Research UK / / A4994; United States / NCI NIH HHS / CA / R03 CA132188-02; United Kingdom / Cancer Research UK / / C588; United States / NCI NIH HHS / CA / P01-CA42101; United States / NCI NIH HHS / CA / R01-CA34382; United States / NIEHS NIH HHS / ES / 5P30ES07048; United States / NCI NIH HHS / CA / CA132188; United Kingdom / Cancer Research UK / / 10589; United States / NCI NIH HHS / CN / N01 CN005230; United States / NCI NIH HHS / CA / CA32262; United Kingdom / Cancer Research UK / / C569/A5030; United States / NCI NIH HHS / CA / R03 CA132188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS98767; NLM/ PMC2729286
  •  go-up   go-down


72. King R, Googe PB, Page RN, Mihm MC Jr: Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. Mod Pathol; 2005 Aug;18(8):1043-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
  • A single case of lentiginous melanocytic hyperplasia overlying a dermatofibroma has been reported, however, nevi and melanoma have to the best of our knowledge, not been previously reported.
  • There were nine females and five males ranging in age from 30 to 64 years and anatomic sites included back (five), arm (six), flank (two), and leg (one).
  • The clinical diagnosis ranged from dermatofibroma to desmoplastic melanoma.
  • Histologically, the melanocytic lesions included junctional, compound, and dermal nevi, and malignant melanoma in situ.
  • In the case of the melanoma in situ, the dermatofibroma abutted the epidermis.
  • Awareness of this association will aid in the correct diagnosis, and immunohistochemical studies will help in the differentiation of these two cell populations.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Melanocytes / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Factor XIIIa / analysis. Female. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Neoplasm Proteins / analysis. Nevus / metabolism. Nevus / pathology. Proto-Oncogene Proteins c-kit / analysis. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803191.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 2.3.2.13 / Factor XIIIa; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


73. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. J Surg Res; 2007 Dec;143(2):372-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
  • TRD has been shown to induce apoptosis of melanoma cells in vitro.
  • Therefore, the effects of TRD on disseminated melanoma were evaluated in a mice model.
  • METHODS: After general anesthesia, a midline laparotomy was performed and 1.5 million malignant melanoma cells (B78-D14) were applied in the spleen and 1 million cells at the back (C57BL/6).
  • CONCLUSIONS: The i.p. and i.v. therapies reduce total tumor weight and number of metastatic lesions of disseminated malignant melanoma in a dose-dependent fashion in mice.
  • Our encouraging findings should be further confirmed in clinical studies examining the influence of TRD in patients with disseminated malignant melanoma for whom prognosis still remains dismal.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Melanoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taurine / analogs & derivatives. Thiadiazines / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17612567.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine
  •  go-up   go-down


74. Cotter MA, Tristani-Firouzi P: Unsuitability of organ donation from a patient with a history of melanoma? J Am Acad Dermatol; 2006 Jun;54(6):1096-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsuitability of organ donation from a patient with a history of melanoma?
  • A 52-year-old man with a history of melanoma presented to the emergency department with a massive intracranial hemorrhage.
  • Three years before presentation, the patient had undergone wide excision of a 3.75-mm melanoma from his back with sentinel lymph node biopsy, which yielded negative findings.
  • Although there are no specific guidelines for candidacy of organ donation from patients with a history of melanoma, there are several reports of donor-derived melanoma in organ transplant recipients, most with grave consequences.
  • [MeSH-major] Melanoma. Skin Neoplasms. Tissue Donors. Tissue and Organ Procurement / standards

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713480.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Geller AC, Emmons KM, Brooks DR, Powers C, Zhang Z, Koh HK, Heeren T, Sober AJ, Li F, Gilchrest BA: A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer; 2006 Aug 15;107(4):806-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial to improve early detection and prevention practices among siblings of melanoma patients.
  • BACKGROUND: Identifying high-risk individuals for melanoma education and risk reduction may be a viable strategy to curb the incidence of melanoma, which has risen precipitously in the past 50 years.
  • The first-degree relatives of melanoma patients represent a risk group who may experience a 'teachable moment' for enhanced education and risk reduction.
  • METHODS: We report a randomized trial testing an intervention that provided personalized telephone counseling and individually tailored materials to siblings of recently-diagnosed melanoma patients.
  • The purpose of this study was to test whether an intervention could lead to improvements in siblings' skin cancer risk reduction practices.
  • Families in the usual care arm received the suggestion from the physician that patients diagnosed with melanoma notify the family members about their diagnosis and encourage the family members to be screened.
  • At 12 months, intervention siblings were more likely to examine all moles, including those on the back (OR, 1.76; 95% CI, 1.06-2.91).
  • Compared with baseline, the number of participants in both groups that had received a skin cancer examination more than doubled, with no differences between groups.
  • CONCLUSIONS: This study is the one of the first, to our knowledge, to address skin cancer risk-reduction strategies in a sample of individuals who have a recent family diagnosis of melanoma.
  • Diagnosis of melanoma in a family member provides an important opportunity to intervene with others in that family.
  • The components of the intervention may provide a useful foundation for future efforts to target the more than half million siblings at risk for melanoma, a lethal but preventable disease.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Melanoma / diagnosis. Melanoma / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Early Diagnosis. Female. Humans. Male. Middle Aged. Risk Factors. Self-Examination. Siblings

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832795.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA76333
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


76. Hofmann MA, Sterry W, Trefzer U: Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit? Jpn J Clin Oncol; 2007 Mar;37(3):224-9
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
  • BACKGROUND: There is currently no chemotherapy or chemoimmunotherapy regimen that has shown impact on survival in patients with metastatic melanoma.
  • From a safety and practical point of view, there was no draw-back on treating patients in a non-intensive care unit.
  • CONCLUSION: This complex and highly toxic chemoimmunotherapeutic regimen should not be considered as standard therapy in patients with metastatic malignant melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472972.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Interferon-alpha; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


77. Mineo JF, P-Ruchoux MM, Pasquier D, Rigolle H, Assaker R: [Primitive malignant melanoma arising in a spinal nerve root. A case report]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):133-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant melanoma arising in a spinal nerve root. A case report].
  • We report the fourth case of primitive malignant melanoma arising in a spinal nerve root.
  • A 39-year-old woman complained of one-year low back pain radiating to the right thigh and knee, and loss of 7 kg.
  • Due to the scalloping of L3/L4 foramen with root enlargement and slow evolution (more than one year between the first symptom and surgery without clinical worsening), the initial preoperative diagnosis was L3 schwannoma.
  • Immunohistochemistry showed melanin, HMB-45 and S100 positivity, but reticulin was negative (that eliminates malignant melanocytic schwannoma).
  • So, the final diagnosis was intradural primitive malignant melanoma.
  • Specific MRI sequences can eliminate adipose tissue tumor, but diagnosis between melanin and methemoglobin is still difficult.
  • According to the index of proliferation, a primitive central melanocytic lesion can be a meningeal melanocytoma (considered as benign) or a primitive malignant melanoma.
  • These tumors show identical protein expressions in immunohistochemistry, and their prognosis is very variable (some long-term remissions are reported for malignant melanomas and fast disseminations are described for meningeal melanocytomas treated by sub-total surgery).
  • The L3/L4 foramen scalloping is unusual for a malignant lesion with theoretic high-speed development.
  • The histological features of malignant lesion with benign clinical features lead to interrogation upon the actual pathologic classification.
  • [MeSH-major] Melanoma / pathology. Spinal Neoplasms / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Cell Proliferation. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Melanins / metabolism. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Neurologic Examination. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840974.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


78. Simeone S, Laterza MM, Scaravilli G, Capuano S, Serao M, Orabona P, Rossi R, Balbi C: Malignant melanoma metastasizing to the uterus in a patient with atypical postmenopause metrorrhagia. A case report. Minerva Ginecol; 2009 Feb;61(1):77-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastasizing to the uterus in a patient with atypical postmenopause metrorrhagia. A case report.
  • The uterine metastases of melanoma are very rare.
  • The patient was discharged with a diagnosis of uterine fibromatosis and called back to go through a complete laparoscopic hysterectomy and bilateral adnexectomy.
  • The immunohistochemistry of the surgical sample was able to confirm the hypothesized relationship between the nevus and the metastases, thus leading to the diagnosis of malignant melanoma metastases, genital tract.
  • The nature of the uterine bleedings can be ascribed to atrophy, dysfunctional matters (dysfunctional uterine bleeding, DBU), benign organic alterations, only in 7-10% of cases to endometrial cancer and more rarely to metastatic tumours, as well as this case of melanoma.
  • [MeSH-major] Endometrial Neoplasms / complications. Endometrial Neoplasms / secondary. Melanoma / complications. Melanoma / secondary. Metrorrhagia / etiology. Postmenopause. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Hysterectomy / methods. Hysteroscopy / methods. Immunohistochemistry. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204664.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


79. Siddaraju N, Yaranal PJ, Mishra MM, Soundararaghavan J: Fine needle aspiration cytology in recurrent amelanotic melanoma: a case report. Acta Cytol; 2007 Sep-Oct;51(5):829-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology in recurrent amelanotic melanoma: a case report.
  • BACKGROUND: Amelanotic melanoma can mimic a wide variety of epithelial and nonepithelial malignant tumors.
  • Varied cytomorphology of melanoma has been described on exfoliative and fine needle aspiration cytology (FNAC).
  • We report a case of recurrent amelanotic melanoma to highlight its varied cytomorphologic features, which may cause diagnostic problems on cytologic and on histologic examinations.
  • CASE: A 63-year-old male presented with nodular swellings in the right anterior chest wall, right axilla and back.
  • FNAC revealed malignant cells with highly varied morphology with plasmacytoid and pleomorphic malignant cells with occasional fibrocollagenous tissue strands showing adherent neoplastic cells.
  • A cytologic diagnosis of pleomorphic malignant tumor was suggested, and the original histologic slides were reviewed; they showed a striking alveolar pattern that vaguely resembled an alveolar rhabdomyosarcoma.
  • A final diagnosis of amelanotic melanoma was made.
  • CONCLUSION: Awareness of the highly varied cytomorphology of amelanotic melanoma minimizes the diagnostic difficulty on fine needle aspiration smears.
  • [MeSH-major] Melanoma, Amelanotic / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910357.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Gillgren P, Brattström G, Frisell J, Persson JO, Ringborg U, Hansson J: Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res; 2005 Apr;15(2):125-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations.
  • The prognostic impact of different anatomical sites in patients with cutaneous malignant melanoma (CMM) has been widely debated and requires further elucidation.
  • There was a significantly increased risk of CMM-specific death in patients with a primary tumour site in the middle and lower back (HR=1.8, P=0.04) and in the supramammary and mammary area (HR=1.8, P=0.05).
  • When all areas were analysed in pairs, the dorsal shoulder, superior back and clavicular area also showed a worse prognosis.
  • It can be concluded that the tumour site is of prognostic importance, and that the middle and lower back and supramammary and mammary areas are independent factors related to a poor prognosis.
  • [MeSH-major] Melanoma / mortality. Skin Neoplasms / mortality
  • [MeSH-minor] Aged. Diagnosis, Computer-Assisted / methods. Female. Follow-Up Studies. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Humans. Imaging, Three-Dimensional. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasms, Multiple Primary / ultrastructure. Prognosis. Proportional Hazards Models. Software. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846146.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


81. de Leeuw J, van der Beek N, Neugebauer WD, Bjerring P, Neumann HA: Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage. Lasers Surg Med; 2009 Feb;41(2):96-103
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage.
  • BACKGROUND: The occurrence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK) is increasing all over the world.
  • The detection and diagnosis of NMSC is not optimal in clinical practice.
  • OBJECTIVE: The purpose of the present study was to use a large area skin fluorescence detection system to detect early NMSCs (clinical visible as well as non-visible lesions) in the face, neck, chest, back and hands of patients treated with UV and outdoor workers.
  • RESULTS: In 93 consecutively referred patients positive skin fluorescence was detected in 61 patients.
  • After histological examination the positive fluorescence appeared to be correlated to benign lesions in 28 patients (sebaceous gland hyperplasia in 22 patients) and to (pre-) malignant lesions in 33 patients (actinic keratosis in 29, BCC in 3 and SCC in 1 patient).
  • In five patients the FD technique used in this study appeared to be more sensitive for the identification of (pre-) malignant lesions than the clinical examination.
  • CONCLUSION: Diagnostic skin fluorescence using liposomal encapsulated 5-ALA and a specialised computerised detection and visualisation system offers the possibility for detection of NMSC at an early, pre-clinical stage.
  • The technique is well suited to examine large areas of skin.
  • It also identifies areas of most interest for performing confirmatory skin biopsies, as well as pre-operative assessment of boundaries of skin malignancies, and finally, the technique is applicable in the control and follow-up of skin cancer treatment.
  • [MeSH-major] Early Detection of Cancer. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19226578.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


82. Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N: Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res; 2009;28:13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line.
  • Prior to ninth vaccination, the mice were challenged with B16/F10 melanoma cells by subcutaneous inoculation on the back for the tumor growth model or by tail venous injection for the lung metastasis model.
  • CONCLUSION: These results suggest that vaccination with an autologous endothelial cell line may be effective against melanoma.
  • [MeSH-major] Cancer Vaccines / immunology. Endothelial Cells / immunology. Immunotherapy, Adoptive / methods. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2179-89 [15041739.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):85-90 [14720332.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):507-16 [15542434.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):553-61 [15695399.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Oncology. 2005;69(1):81-7 [16088235.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8201-7 [16299253.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1813-9 [16551866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9208-13 [16754857.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5834-40 [17020991.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):383-90 [18060766.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1160-6 [11017149.001]
  • [Cites] Vaccine. 2000 Dec 8;19(9-10):1294-303 [11137269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Chin Med J (Engl). 1999 Feb;112(2):157-61 [11593585.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7846-54 [11691802.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4182-94 [11751519.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2034-42 [11929822.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2567-75 [11980651.001]
  • [Cites] Immunol Invest. 2002 Feb;31(1):51-69 [11990463.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1575-84 [12070285.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3906-27 [12228212.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21831-6 [12651849.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1815-23 [12750177.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • (PMID = 19183492.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Other-IDs] NLM/ PMC2646687
  •  go-up   go-down


83. Hantschke M, Mentzel T, Rütten A, Palmedo G, Calonje E, Lazar AJ, Kutzner H: Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol; 2010 Feb;34(2):216-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma.
  • Clear cell sarcoma (CCS) of tendons and aponeuroses/malignant melanoma (MM) of soft parts is a rare tumor and in the majority of cases presents a characteristic reciprocal translocation t(12;22)(q13;q12) that results in fusion of the EWS and ATF1 genes.
  • Most tumors (n = 9) were located on the extremities, 2 tumors arose on the back, and 1 on the abdomen.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087159.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA093459; United States / NCI NIH HHS / CA / 1P50CA09345-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Melanins
  •  go-up   go-down


84. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M: A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs; 2007 Jun;25(3):247-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
  • There is no effective systemic therapy for disseminated metastatic melanoma.
  • Data suggest that endothelin may play a role in pathophysiology of melanoma and that the dual endothelin receptor antagonist bosentan may have anti-tumor activity.
  • This multicenter, open-label, single-arm, prospective, proof-of-concept study assessed the effects of bosentan monotherapy (500 mg oral tablets, bid) on tumor response in patients with stage IV metastatic melanoma.
  • Among the 35 patients included in this study with stage IV metastatic melanoma, 21 (60%) were stage M1C, 10 (29%) stage M1B and 4 (11%) stage M1A (American Joint Committee on Cancer [AJCC] classification).
  • Nine patients (26%) had received prior therapy for stage IV melanoma.
  • The most frequent adverse events were typical for the underlying disease or known to be associated with bosentan: headache (43%), fatigue (34%), nausea (31%), back pain (23%) and abnormal hepatic function (23%).
  • Bosentan might have benefit in disease stabilization in certain patients with metastatic melanoma and deserves further investigation in combination with other anticancer drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endothelin Receptor Antagonists. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021960.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin Receptor Antagonists; 0 / RNA, Messenger; 0 / Receptors, Endothelin; 0 / Sulfonamides; 0 / Tablets; Q326023R30 / bosentan
  •  go-up   go-down


85. Vano-Galvan S, de las Heras E, Aguayo-Leyva I, Jaen P: Dermatoscopy for in vivo diagnosis of malignant melanoma. Aust Fam Physician; 2009 Jun;38(6):420-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy for in vivo diagnosis of malignant melanoma.
  • Clinically, a 12 mm long, slightly elevated, brown lesion with variegate pigmentation was observed on his back.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521586.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


86. Downs NJ, Schouten PW, Parisi AV, Turner J: Measurements of the upper body ultraviolet exposure to golfers: non-melanoma skin cancer risk, and the potential benefits of exposure to sunlight. Photodermatol Photoimmunol Photomed; 2009 Dec;25(6):317-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the upper body ultraviolet exposure to golfers: non-melanoma skin cancer risk, and the potential benefits of exposure to sunlight.
  • The risk of developing a skin cancer or an eye disease as a result of incidental exposure to naturally occurring ultraviolet radiation in the outdoor environment is proportionately high in a Queensland population compared with fair-skinned population groups residing in comparable Northern Hemisphere latitudes.
  • METHODS: The erythemal and vitamin D effective ultraviolet exposure measured to the forearm, upper back and vertex are presented for individuals playing golf under various atmospheric conditions in a 7-month period extending from summer to winter.
  • RESULTS: Mean summertime exposures were measured in the 2008 study period as be 1.4, 2.2 and 3.2 standard erythema doses (SED) at forearm, upper back and vertex sites, respectively, compared with respective wintertime forearm, upper back and vertex exposures of 0.2, 0.3 and 0.5 SED, where summertime exposures were recorded in the mean solar zenith angle (SZA) ranges of 56-59 degrees and wintertime exposures were recorded in the mean SZA range 74-83 degrees.
  • Vitamin D(3) effective exposures were determined to vary from between 225, 325 and 475 J/m(2) during summer and 48, 59 and 88 J/m(2) during winter for the respective forearm, upper back and vertex body sites measured in the above mean SZA ranges.
  • [MeSH-major] Golf. Neoplasms, Radiation-Induced / epidemiology. Skin Neoplasms / etiology. Sunlight

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906167.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


87. Ferrari A, Lozzi GP, Fargnoli MC, Peris K: Dermoscopic evolution of a congenital combined nevus in childhood. Dermatol Surg; 2005 Nov;31(11 Pt 1):1448-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermoscopically, combined nevus can mimic melanoma owing to the presence of dermoscopic features common to both types of lesions.
  • RESULTS: An asymptomatic plaque with a central blue area and peripheral brown pigmentation located on the back of a 13-year-old boy was diagnosed dermoscopically as combined nevus.
  • Surgical excision is recommended when clinical and dermoscopic features are equivocal and the diagnosis of melanoma cannot be ruled out.
  • [MeSH-major] Dermoscopy. Nevus, Blue / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Back. Diagnosis, Differential. Humans. Male. Melanoma / diagnosis

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416618.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Nguyen QH, Szeto E, Mansberg R, Mansberg V: Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies. Clin Nucl Med; 2005 Apr;30(4):241-3
MedlinePlus Health Information. consumer health - Staphylococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old woman was referred for a bone scan to assess back pain on a background of breast cancer, melanoma, and rheumatic heart disease.
  • [MeSH-minor] Aged. Back Pain / diagnosis. Back Pain / etiology. Breast Neoplasms / complications. Breast Neoplasms / radionuclide imaging. Diagnosis, Differential. Female. Gamma Cameras. Humans. Melanoma / complications. Melanoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764879.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Milne E, Simpson JA, English DR: Appearance of melanocytic nevi on the backs of young Australian children: a 7-year longitudinal study. Melanoma Res; 2008 Feb;18(1):22-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The number of nevi has been established as the strongest known risk factor for melanoma, but whether the rate at which nevi appear during childhood varies by age is not well understood.
  • Children were assessed at ages 6, 10 and 12 years, with nevi on the back counted from photographs.
  • If so, it suggests that skin cancer prevention campaigns should target older children and adolescents as well as younger children.
  • [MeSH-major] Melanoma / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Australia. Back. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Longitudinal Studies. Male. Melanosis. Risk Factors. Skin Pigmentation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227704.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Trindade MR, Blaya R, Trindade EN: [Not Available]. J Minim Access Surg; 2009 Jan;5(1):17-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old male patient with possible splenic soft tissue melanoma metastasis was referred to our hospital.
  • He had a history of an excised soft tissue melanoma from his back eight months earlier, and the control abdominal computer tomography (CT) scan revealed a hypodense spleen lesion.
  • The splenectomy was performed and the histological examination revealed a melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547681.001).
  • [ISSN] 0972-9941
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Melanoma / metastasis / spleen
  •  go-up   go-down


91. Coras B, Landthaler M, Stolz W, Vogt T: Dysplastic melanocytic nevi of the lower leg: sex- and site-specific histopathology. Am J Dermatopathol; 2010 Aug;32(6):599-602
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this retrospective histopathology study, we compared DN-LW (N = 42) with appropriate control groups of (1) DN of the lower leg of men (N = 20; DN-LM), (2) DN from the back of women (N = 20), (3) common nevi of the lower leg of women (N = 40), and (4) levels 1-2 superficial spreading melanoma of the lower leg of women (N = 20).
  • Compared with dysplastic nevi on the back, DN-LW were smaller in diameter and exhibited a significantly higher score for pagetoid spread (P < 0.05).
  • Knowing this profile may lower the risk of misdiagnosing DN-LW and melanoma of the lower leg of women.
  • [MeSH-major] Diagnostic Errors / prevention & control. Dysplastic Nevus Syndrome / diagnosis. Melanocytes / pathology. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Back. Diagnosis, Differential. Female. Humans. Leg. Male. Melanoma / diagnosis. Middle Aged. Retrospective Studies. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2012 Dec;34(8):853-5 [22481498.001]
  • (PMID = 20534984.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Chiu V, Won E, Malik M, Weinstock MA: The use of mole-mapping diagrams to increase skin self-examination accuracy. J Am Acad Dermatol; 2006 Aug;55(2):245-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of mole-mapping diagrams to increase skin self-examination accuracy.
  • BACKGROUND: Monthly skin self-examination (SSE) is associated with reduced incidence of advanced melanoma, but SSE is prone to error in detecting early changes of melanoma.
  • LIMITATIONS: This study was limited by sample size, only addressed lesions on the back, and did not involve actual melanomas in study participants.
  • CONCLUSIONS: Mole-mapping diagrams may improve SSE accuracy, and may be useful as a simple, cost-effective intervention in reducing melanoma mortality.
  • [MeSH-major] Melanoma / diagnosis. Self-Examination / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844506.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA106592
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


93. Situm M, Bulat V, Buljan M, Puljiz Z, Situm V, Bolanca Z: Senile lentigo--cosmetic or medical issue of the elderly population. Coll Antropol; 2010 Apr;34 Suppl 2:85-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Senile lentigo or age spots are hyperpigmented macules of skin that occur in irregular shapes, appearing most commonly in the sun-exposed areas of the skin such as on the face and back of the hands.
  • Senile lentigo is a common component of photoaged skin and is seen most commonly after the age of 50.
  • There are many disscusions on whether senile lentigo represents a melanoma precursor, namely lentigo maligna melanoma and, if there is a need for a regular follow up in cases of multiple lesions.
  • Clinical observations sometimes report that in the location of the newly diagnosed melanoma, such lesion preexsisted.
  • However, the observation of the possible association of senile lentigo with the melanoma development makes us cautious in the assessment of this lesion.
  • [MeSH-major] Lentigo / pathology. Melanoma / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302707.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Cosmetics
  •  go-up   go-down


94. Iglesias-Bartolomé R, Crespo PM, Gomez GA, Daniotti JL: The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. Inhibitory effect of brefeldin A and monensin. FEBS J; 2006 Apr;273(8):1744-58
Hazardous Substances Data Bank. MONENSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we characterized in both GD3 ganglioside-expressing Chinese hamster ovary (CHO)-K1 and SK-Mel 28 melanoma cells the intracellular trafficking and subcellular localization of the mouse monoclonal antibody to GD3, R24.
  • Taken together, our results indicate that the GD3-R24 complex is endocytosed in GD3-expressing cells, accumulates in the recycling endosome, and is transported back to the plasma membrane via a route that involves clathrin-coated vesicles.
  • [MeSH-minor] Animals. Blotting, Western. CHO Cells / drug effects. CHO Cells / metabolism. Clathrin-Coated Vesicles / metabolism. Cricetinae. Dynamin II / metabolism. Electrophoresis, Polyacrylamide Gel. Humans. Melanoma / drug therapy. Melanoma / metabolism. Microscopy, Confocal. Protein Transport. Subcellular Fractions

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623710.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gangliosides; 20350-15-6 / Brefeldin A; 62010-37-1 / ganglioside, GD3; 906O0YJ6ZP / Monensin; EC 3.6.5.5 / Dynamin II
  •  go-up   go-down


95. Borges SZ, Bakos L, Cartell A, Wagner M, Agostini A, Lersch E: Distribution of clinical-pathological types of cutaneous melanomas and mortality rate in the region of Passo Fundo, RS, Brazil. Int J Dermatol; 2007 Jul;46(7):679-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the characteristics of all cases of primary cutaneous melanoma during the period 1995-2001, registered at pathology departments in the region of Passo Fundo.
  • METHODS: The sample studied consisted of 229 primary cutaneous melanoma lesions, identified by anatomopathological reports, in 218 patients.
  • RESULTS: The most frequent tumor site was in the back of men (49.5%) and in the lower limbs of women (33.1%).
  • CONCLUSIONS: In the sample studied the most common sites were in the back of men and in the legs of women.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614794.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Jeong WC, Kim KJ, Ju HW, Back HK, Kim HK, Im SY, Lee HK: Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice. Anticancer Res; 2010 Sep;30(9):3421-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this study, the effects of inhibitors of cPLA2, 5-lipoxygenase (5-LO), and cyclooxygenase (COX)-2 on pulmonary metastasis formation by B16F10 melanoma cells were investigated.
  • [MeSH-minor] Animals. Cyclooxygenase 2 / metabolism. Enzyme Inhibitors / pharmacology. Female. Lipoxygenase Inhibitors. Matrix Metalloproteinase Inhibitors. Melanoma, Experimental / secondary. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944117.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.1.1.4 / Phospholipases A2, Cytosolic
  •  go-up   go-down


97. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N: Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des; 2008;14(11):1049-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors which usually do not express ASS include melanoma, hepatocellular carcinoma, some mesotheliomas and some renal cell cancers.
  • Citrulline can be recycled back to arginine in normal cells which express ASS, whereas ASS(-) tumor cells cannot.
  • A pegylated form of ADI (ADI-PEG20) has been formulated and has shown in vitro and in vivo activity against melanoma and hepatocellular carcinoma.
  • ADI-PEG20 induces apoptosis in melanoma cell lines.
  • However, arginine deprivation can also induce ASS expression in certain melanoma cell lines which can lead to in vitro drug resistance.
  • Phase I and II clinical trials with ADI-PEG20 have been conducted in patients with melanoma and hepatocellular carcinoma, and antitumor activity has been demonstrated in both cancers.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1982 May 10;257(9):5061-7 [6279658.001]
  • [Cites] Biochem J. 1983 Nov 15;216(2):281-5 [6661196.001]
  • [Cites] J Biochem. 1985 Nov;98(5):1395-403 [4086486.001]
  • [Cites] Arch Biochem Biophys. 1987 Jul;256(1):343-53 [3038025.001]
  • [Cites] Mol Endocrinol. 1988 May;2(5):444-51 [2843756.001]
  • [Cites] J Biol Chem. 1988 Nov 5;263(31):16388-94 [3182797.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):345-9 [2403840.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):1935-43 [2005889.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2932-9 [1903327.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):244-9 [1568792.001]
  • [Cites] Melanoma Res. 1992 Sep;2(3):191-6 [1450673.001]
  • [Cites] Arch Biochem Biophys. 1993 Mar;301(2):237-43 [8460937.001]
  • [Cites] Jpn J Cancer Res. 1993 Nov;84(11):1195-200 [8276724.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):148-53 [7575582.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):840-6 [7591961.001]
  • [Cites] FEBS Lett. 1996 Dec 16;399(3):310-2 [8985169.001]
  • [Cites] Hepatology. 1997 Apr;25(4):964-9 [9096605.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):E79-86 [9688877.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 [9806879.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):10-4 [10405315.001]
  • [Cites] Adv Exp Med Biol. 1999;457:621-9 [10500842.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18717-27 [15772076.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):247-53 [15886013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14238-43 [16176982.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7660-8 [16234528.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):30-5 [16356828.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):508S-512S [16470022.001]
  • [Cites] Curr Opin Mol Ther. 2006 Jun;8(3):240-8 [16774044.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2006;60:483-9 [17013367.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7126-31 [17145837.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):897-905 [17096330.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jan;22(1):86-91 [17201887.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]
  • [Cites] Proteomics. 2007 Feb;7(4):565-77 [17309102.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):573-6 [12888832.001]
  • [Cites] Leukemia. 2000 May;14(5):826-9 [10803513.001]
  • [Cites] Mol Cells. 2000 Jun 30;10(3):331-7 [10901172.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):800-10 [10952786.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Nov 10;83(1-2):1-8 [11072090.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):155-62 [12065090.001]
  • [Cites] Med Sci Monit. 2002 Jul;8(7):BR248-53 [12118186.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5443-50 [12359751.001]
  • [Cites] Genes Cells. 2003 Jan;8(1):65-79 [12558800.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):613-23 [12592378.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):165-70 [12618329.001]
  • [Cites] Mol Cell Biochem. 2003 Feb;244(1-2):177-85 [12701828.001]
  • [Cites] Eur J Biochem. 2003 May;270(9):1887-99 [12709047.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):723-8 [12866032.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):907-14 [12942125.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6 [14571701.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 15;66(10):1945-52 [14599552.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 9;313(2):443-6 [14684182.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52504-10 [14570901.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):826-33 [14770441.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36192-200 [15192091.001]
  • [Cites] Clin Sci (Lond). 2004 Oct;107(4):371-9 [15157183.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):502-8 [15382078.001]
  • [Cites] Anticancer Drugs. 2004 Oct;15(9):825-33 [15457122.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S [15465796.001]
  • [Cites] Br J Cancer. 1974 Jul;30(1):50-9 [4528778.001]
  • [Cites] Cytogenet Cell Genet. 1979;23(3):171-81 [219990.001]
  • [Cites] Br J Cancer. 1979 Jun;39(6):613-20 [444403.001]
  • [Cites] Eur J Biochem. 1979 Jun;97(1):29-35 [477671.001]
  • [Cites] J Biol Chem. 1981 Nov 25;256(22):11826-31 [6170638.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2246-53 [7061421.001]
  • (PMID = 18473854.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109578-02; United States / NCI NIH HHS / CA / R01CA109578; United States / NCI NIH HHS / CA / CA109578-03; United States / NCI NIH HHS / CA / R01 CA109578; United States / NCI NIH HHS / CA / CA109578-01; United States / NCI NIH HHS / CA / CA109578-02; United States / NCI NIH HHS / CA / R01 CA109578-01; United States / NCI NIH HHS / CA / R01 CA109578-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 94ZLA3W45F / Arginine; EC 3.- / Hydrolases; EC 3.5.3.6 / ADI PEG20; EC 6.3.4.5 / Argininosuccinate Synthase
  • [Number-of-references] 75
  • [Other-IDs] NLM/ NIHMS287629; NLM/ PMC3096551
  •  go-up   go-down


98. Hofmann-Wellenhof R: [Change in color of a papillomatous nevus]. Hautarzt; 2010 Apr;61(4):343-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 43-year-old patient presented with a skin tumor on her back that had been slowly changing in color.
  • One part exhibited characteristics of a melanoma (blue-white veil, irregular pigment network) and the other an unspecific pattern of a papillomatous nevus.
  • Histological examination of the completely excised tumor revealed a nevus-associated melanoma.
  • [MeSH-major] Melanoma / pathology. Nevus / pathology. Papilloma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2002 Jun;12(3):271-8 [12140384.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):653-6 [16120160.001]
  • [Cites] Br J Dermatol. 2009 Sep;161(3):510-4 [19466956.001]
  • (PMID = 20361319.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. English DR, Milne E, Simpson JA: Sun protection and the development of melanocytic nevi in children. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2873-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood sun exposure causes nevi (and melanoma), but there is little evidence regarding the effectiveness of sun protection strategies on the number of nevi.
  • The outcome was number of nevi on the back 6 years after baseline, when the children were 12 years old.
  • Using sunscreen on the back when it was uncovered was not associated with number of nevi (P = 0.59).
  • [MeSH-major] Nevus, Pigmented / prevention & control. Protective Clothing. Skin Neoplasms / prevention & control. Sunlight / adverse effects. Sunscreening Agents
  • [MeSH-minor] Back. Child. Dose-Response Relationship, Radiation. Female. Humans. Male. Surveys and Questionnaires. Western Australia / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365003.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


100. Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS: Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:83-6
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient is a 49-year-old male with a history of a changing 'mole' on the left upper back.
  • The melanocytic component strongly expressed melanoma antigen recognized by T-cells-1 (MART-1) and HMB-45.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544054.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down






Advertisement